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 Muscle pathology has unique relevance in many different fields 
of veterinary research, ranging from the diagnostics, to the comparative 
medicine involving animal models of human diseases, to the animal based 
food safety. The Laboratory of Comparative of Neuromuscular Disorders 
was established decades ago at the Department Veterinary Medicine of 
Naples in order to contribute to the knowledge of muscle pathology in 
domestic animals using modern techniques and undertaking international 
scientific collaborations. In this context, the project of this doctoral thesis 
had the main purpose to produce new scientific data in at least two interest 
area: the etiopathogenesis of inflammatory myopathies and skeletal muscle 
aging. Thus, the experimental results of four research project conducted in 
four different species are presented, including: 1) Inflammatory myopathy 
in horses affected by chronic piroplasmosis; 2) Lymphoplasmacytic 
myositis and expression of Major Histocompatibility Complex class I and 
II in ovine muscular sarcocystosis; 3) Age related skeletal muscle atrophy 
and upregulation of autophagy in dogs; 4) Expression and biochemical 
properties of cellular Prion protein in skeletal muscle of aged cows. 
In the first and second chapters of the thesis, two inflammatory myopathies 
associated with parasites having or not having a specific tropism for 
skeletal muscle (Sarcocystis tenella and Theileria equi -Babesia caballi, 
respectively) are explored.  
In the first study, an inflammatory myopathy characterized by a mainly 
CD8-CD4+ lymphocytic population and fiber degeneration is described in 
16 horses serologically positive for equine piroplasms with clinical signs 
and serum biochemical evidence of a myopathy. To test the hypothesis of 
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circulating autoantibodies directed against an unknown muscular antigen, 
the serum from affected horses was tested by indirect immunofluorescence 
to sections of normal equine muscle. In all cases, distinct sarcolemmal 
staining was detected in sections incubated with serum from affected 
horses, in contrast to sections incubated with phosphate-buffered saline or 
equine control sera. Furthermore, a significant increase of interferon-γ, 
interleukin-12, and tumor necrosis factor-α gene expression by compared 
to healthy controls was revealed by Reverse transcription polymerase chain 
reaction (RT-PCR). Thus, we concluded that inflammatory myopathy 
associated with equine piroplasmosis may involve an autoimmune 
pathogenesis with upregulation of inflammatory cytokines that may cause 
myofiber atrophy and degeneration. 
The aim of the second chapter, leading with muscle inflammation in ovine 
muscular sarcosytosis, was to investigate if parasitized muscle fibers could 
play a role in immune-stimulation, as sporadically described in accidental 
muscular sarcocystosis in definitive hosts.  
Skeletal muscle samples from 78 sheep presenting muscular sarcocysts 
revealed inflammatory changes in 69% of cases, consisting of an 
endomysial lymphoplasmacellular infiltrate, with attendant myofiber 
degeneration and necrosis. The predominant T cell populations were 
CD3+, CD8+ with lesser numbers of CD4+ and CD79α+ cells. Eosinophils 
were constantly absent. Notably, moderate to strong sarcolemmal labeling 
to Major histocompatibility complex (MHC) I and II was found both in 
biopsies with evident inflammatory infiltrate and in cases without 
inflammation. The wall of the cysts resulted strongly positive to MHC I 
Abstract 
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and II, and occasionally co-localized with the membrane associated protein 
Dystrophin. Our data suggest that muscle fibers respond to the presence of 
cysts by expression of MHC I and II that can play a role in stimulating and 
maintaining the lymphoplasmacellular inflammation. The possible role of 
MHC I on the cyst wall is discussed, but basically more research is needed 
in order to evaluate its possible involvement in inflammation. Moreover 
we speculated about the possibility that the abnormal expression of MHC I 
and II on muscle fibers is not only typical of myopathies having an 
immune-mediated pathogenesis but also of myositis associated with 
muscular parasites. 
 The last two chapters of the thesis are dedicated to muscle aging, 
and in particular to the role of autophagy in canine sarcopenia and of 
cellular prion protein in bovine muscle aging. Sarcopenia, the age related 
loss of muscle mass and strength, is a multifactorial condition that occurs 
in a variety of species and represents a major healthcare concern in human 
medicine. We evaluated the expression of three markers of autophagy, 
Beclin 1, LC3 and p62, in muscle wasting of 25 geriatric dogs, to establish 
whether the levels of autophagy change with increasing age. Our results 
indicated a marked intracytoplasmic staining for Beclin 1 and LC3 in 80% 
of the muscle samples from the older dogs and a significantly greater 
expression of LC3 II and Beclin 1, by Western blotting. The results of the 
study suggest that enhanced autophagy might be one of the factors 
underlying muscle atrophy in canine age related muscle wasting. 
 Finally, we explored the expression and biochemical properties 
of cellular prion protein (PrPC) in skeletal muscle of cows as well as their 
Abstract 
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possible changes in geriatric animals. PrPC over expression has been 
described in many different human neuromuscular disorders but little is 
known about PrPC in health and disease in bovine muscle tissue. Skeletal 
muscle and brain samples of 12 aged and 8 young Podolica cows were 
collected and compared by histomorphological techniques as well as 
several experiments involving immunoblot and specifically analyzing the 
amount of PrPC, its glycosylation profile, proteinase resistance, solubility 
levels and tendency to aggregate. Histologically, muscle biopsies of aged 
cows showed typical myopathic features already described in bovine 
sarcopenia. Immunohistochemistry for PrP revealed a distinct granular 
positivity in intramuscular nerve branches and muscle spindles in all cases. 
Membrane immunopositivity was more prominent on angular atrophic 
fibers. Increased levels of positivity were found in degenerated fibers 
(desmin depleted) with a positive labeling of rimmed vacuoles. Prion 
protein positivity levels was also significantly increased in cases displaying 
inflammatory changes. No differences between muscles and brains of 
young and old animals were detected by quantitative immunoblot and 
Proteinase K titration. The glycoform profile and the molecular mass of 
PrPC in muscle samples appeared slightly different compared to the brain. 
Sucrose gradient velocity sedimentation gave variable results, with a 
generally lower amount of PrP in high density sucrose fractions in the 
muscle compared to the brain. After high speed centrifugation the majority 
of muscle PrPC was found in the soluble fraction, without significant 
differences between young and old animals. Our preliminary data suggest 
that: 1) the amount and the main biochemical properties of prion protein do 
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not change with age, 2) PrPC is overexpressed in degenerated, vacuolated 
and angular muscle fibers; 3) The glycoform profile of PrPC differs 
between brain and muscle tissue. 
In conclusion, the main innovative aspects of this thesis are: 
1) The first description in the literature of a likely immune-mediated 
myositis occurring in chronic equine piroplasmosis 
2) The demonstration of high prevalence of lymphoplasmacellular 
myositis in ovine muscular sarcocystosis implying the 
overexpression of MHC I on muscle fibers as well as on the cyst 
wall. 
3) The report of enhanced autophagy in age-related muscle atrophy in 
dogs. 
4) The first detailed description of PrPC localization and biochemical 
properties in bovine muscle tissue and its possible involvement in 
neurogenic atrophy, muscle degeneration and chronic 
inflammation.  
 Collectively, these results enhance the relevance of 
morphological studies as starting point to investigate the pathogenesis of 
muscle diseases in veterinary and comparative pathology. 
 
 
   
General Background: 
Skeletal muscle pathology: comparative aspects and personal 
experiences at the Laboratory of Comparative Neuromuscular 
Pathology of Naples:  
 
 Skeletal muscle is an unique and highly specialized tissue 
expressing a wide variety of lesions. The study of muscle diseases in 
veterinary medicine offers the irreplaceable opportunity to compare 
different species, interchanging concepts and scientific approaches from 
human to veterinary medicine and vice- versa. In recent years, veterinary 
skeletal muscle pathology is progressively gaining importance due to its 
interdisciplinary relevance in many fields, ranging from the diagnostics, to 
the comparative medicine involving animal models of human diseases, to 
the animal based food safety. The Laboratory of Comparative 
Neuromuscular Disorders (LCND) was established decades ago at the 
Department of Veterinary Medicine and animal production of Naples in 
order to provide its own contribution to the knowledge about muscle 
pathology in domestic animals using modern techniques and undertaking 
international scientific collaborations. 
Microscopic analysis is essential for the study of muscle pathology in 
human as well as in veterinary medicine. The study of most neuromuscular 
diseases is based on clinical issues, ancillary tests such as 
electromyography, microscopic evaluation of muscle morphology, and, if 
required, molecular and genetic studies. Muscle biopsy, associated to 
histochemical and immunohistological techniques, plays a key role in 
diagnosis of many neuromuscular disorders, likely more than in other 
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tissues (Paciello, 2009). Histochemical techniques (Fig. I.1) are essential 
for the study of muscle tissue for four main reasons. First, they can 
demonstrate selective involvement of different fiber types in certain 
disease processes. Second, they may show an absence of a particular 
enzyme. Third, an excess of a particular substrate can be demonstrated. 
Fourth, they may show structural changes in the muscle which would not 
be apparent with routine histological stains, such as mitochondrial 
abnormalities (Paciello, 2009). While immunohistochemistry is very useful 
in identifying abnormal expression of primary protein abnormalities in 
recessive conditions, it is less helpful in detecting primary defects in 
dominantly inherited disorders. Abnormal immunohistochemical 
expression patterns can be confirmed by Western blot analysis which may 
also be informative in dominant disorders, although its role has yet to be 
established. Besides identification of specific protein defects, 
immunohistochemistry is also helpful in the differentiation of 
inflammatory myopathies by subtyping cellular infiltrates and 
demonstrating up-regulation of subtle immunological parameters. The 
pattern of fiber types can be studied accurately only by subjecting cryostat-
sectioned unfixed, frozen muscle to myofibrillar adenosine triphosfatase 
(ATP) reactions at pHs 4.3, 4.6 and 9.4. 
Some of the most used histochemical techniques are reported in table 1. 
Reference can be made to the book on muscle biopsy of Dubowitz and 
Sewry (2007).  
Specific importance have special histoenzimatic stains such as Oil Red O 
(ORO), PAS (Periodic acid Schiff) and Congo Red in the diagnostics of 
muscle diseases characterized by cytoplasmic accumulations of abnormal 
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material; using these techniques, the basic distinction between lipid (ORO 
positive), glycidic (PAS) or amyloid (Cong Red) deposits can be made in a 
very quick and reliable way on muscle cryosections.  
 
 
 Fig. I. 1 Main histochemical techniques used in the study of muscle tissue in specialized laboratories (from 
Paciello et al., 2009). 
 
Immunohistochemistry, since its introduction in the 1960s, had a 
significant positive impact in the study of neuromuscular disorders as well 
as in the diagnostics field. Overall, it is important to mention that, as for 
enzyme histochemical preparations, muscle specimen preservation by 
freezing is a prerequisite for accurate immunohistochemical and for 
immunoblot analysis as there are only a limited number of antibodies that 
work on paraffin sections. Immunohistochemistry consist in the 
localization of antigens in tissue sections by the use of antibodies as 
specific reagents through antigen antibody interactions. Similar to 
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immunohistochemistry, immunofluorescence can be used to detect the 
location and relative quantity of an antigen on muscle fibers. The technique 
use a fluorescent dye that is covalently attached to the primary or 
secondary antibody. When a light illuminates the fluorescent dye, the light 
is absorbed and the dye emits a different color light which is visible under 
the microscope. Direct immunofluorescence requires only one single-step 
incubation with directly conjugated antibodies, while indirect 
immunofluorescence uses unconjugated primary antibodies which are 
labeled by fluorescently conjugated secondary antibodies in a second-step 
(Paciello, 2009). 
Western blots are used to detect the proteins in homogenized skeletal 
muscle samples by using specific antibodies. It gives information about the 
presence and the relative amount of those proteins, compared with a 
control. The proteins of the sample are electrophoresed into a gel and 
separated based upon molecular weight and charge. In the blotting process, 
they are transferred on a membrane made of nitrocellulose or PVDF by 
applying a current. To detect the antigen blotted on the membrane, a 
primary antibody is incubated with the membrane and then labeled by a 
secondary enzyme conjugated antibody. Finally, the enzyme substrate is 
added which will precipitate upon reaction with the conjugate so that the 
position of the membrane-bound primary antibody will become visible. 
Size approximations can be done by comparing the stained band with that 
of a prestained protein size marker. 
Muscle diseases may be subdivided into six broad categories on the basis 
of sets of fairly distinctive clinicopathologic characteristics: atrophies, 
dystrophies, inflammatory myopathies, metabolic myopathies, "congenital" 
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myopathies, and disorders of neuromuscular transmission (De Girolami, 
1982).  
An extensive review of neuromuscular disorders in humans and animals is 
not the purpose of this section; basic concepts and classifications are 
presented with special attention about personal scientific experiences in the 
LCND of Naples and comparative aspects between different species. 
 
I. Neurogenic atrophies  
 Neuropathic or neurogenic muscular disease refers to those 
conditions in which fiber atrophy is secondary to an interruption of 
innervations resulting from an abnormality of the anterior horn cell, its 
axonal processes, or the neuromuscular junction. The histopathological 
character of denervated muscle fibers is usually pathognomonic: fiber 
becomes smaller and assumes a characteristic angular, sharply contoured 
configuration. The pyknotic nuclei tend to cluster in clumps. With 
progression of the disease, the atrophic, angulated fiber clusters in small 
groups-a process often referred to as group atrophy. Utilizing 
histochemical techniques, one can see that both major fiber types are 
involved. Through the process of collateral sprouting, previously 
denervated muscle fibers may then become reinnervated. The reinnervated 
muscle fiber, however, will assume the fiber type of its new innervations 
resulting in a loss of normal mosaic pattern at the ATPase stains. Such a 
histochemical change is termed fiber-type grouping. Type II fiber atrophy 
is, in contrast, a relatively nonspecific form of muscle atrophy that may 
occur in a wide variety of conditions, including disuse, cachexia, chronic 
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disease, upper motor neuron lesions, and steroid administration (De 
Girolami, 1982).  
In veterinary medicine, the most popular neurogenic muscle disorders are 
probably the neurogenic masticatory muscle atrophy in dogs secondary to 
diseases of trigeminal nerve (i.e, inflammation or neoplasia) the laryngeal 
hemiplegia of the horse and the Equine Motor Neuron Disease (EMND), a 
condition depending on the progressive motor neuron degeneration in the 
spinal cord (Cummings, 1990). Similar conditions have been reported in 
some canine breeds as well.  
 
II. Muscular Dystrophies  
 The muscular dystrophies are a heterogeneous group of inherited 
disorders depending on specific defects of one or more structural protein 
which may lead to muscle fiber necrosis and apoptosis with subsequent 
muscle fiber loss and fibrosis. Since identification of the dystrophin gene 
mutation and protein defect responsible for progressive muscular 
dystrophy types Duchenne and Becker in 1987 (Hoffman, 1988), many 
other protein defects have been identified allowing further classification 
and accurate diagnosis of muscular dystrophies (Sewry, 2000). These gene 
mutations and protein defects are subtyped in sarcolemmopathies with 
sarcolemmal protein deficiencies and in non-sarcolemmal muscular 
dystrophies with defects of nuclear, i.e. emerin, and sarcomeric proteins, 
i.e. myotilin and telethonin, as well as enzymes, i.e. calpain 3, and can be 
documented by immunohistochemistry and by immunoblot analysis.  
The characteristic morphological abnormalities of the most known muscle 
Dystrophy, Duchenne Dystrophy, include: 1) variability in fiber size with a 
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greater than normal size range in the cross-sectional fiber; 2) 
internalization of subsarcolemmal nuclei); 3) degeneration, necrosis, and 
phagocytosis of muscle fibers; 4) regeneration of muscle fibers; and 5) 
proliferation of endomysial connective tissue.  
When a mutation disrupts the reading frame of amino acids (an out-of-
frame mutation), the defect in dystrophin results in a severe phenotype of 
Duchenne Muscle Dystrophy. A mutation, which maintains the reading 
frame (an in-frame mutation) results, less frequently, in the production of 
truncated and only partly functional dystrophin. This mutation leads to the 
more benign phenotype (Monaco et al., 1988) known as Becker muscular 
dystrophy (BMD).  
In 2014 we described one of the rare cases of Becker-like muscular 
dystrophy in a 3-year-old, male Labrador retriever dog. Immunoblotting 
revealed a truncated dystrophin protein of approximately 135 kDa. 
(Baroncelli, 2014). 
Several spontaneous and genetically engineered animal models have been 
demonstrated extremely useful in the study of muscle dystrophies (for 
specific review see Vainzof, 2008). These models generally display similar 
alteration to the human counterpart and are considered extremely important 
tools for genetic, clinic, and histopathological studies. The MDX mouse is 
the most widely used animal model for Duchenne muscular dystrophy, 
even though it is not useful for clinical trials because of its mild disease 
phenotype due to protective uthrophin upregulation. The canine golden 
retriever MD model represents a more clinically similar model of DMD 
due to its larger size and significant muscle weakness. Autosomal recessive 
limb-girdle MD forms models include the SJL/J mice, which develop a 
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spontaneous myopathy resulting from a mutation in the Dysferlin gene, 
being a model for LGMD2B. For the human sarcoglycanopahties (SG), the 
BIO14.6 hamster is the spontaneous animal model for δ-SG deficiency, 
whereas some canine models with deficiency of SG proteins have also 
been identified. All sarcoglycan-null animals display a progressive 
muscular dystrophy of variable severity and share the property of a 
significant secondary reduction in the expression of the other members of 
the sarcoglycan subcomplex and other components of the Dystrophin-
glycoprotein complex. Mouse models for congenital MD include the dy/dy 
(dystrophia-muscularis) mouse and the allelic mutant dy2J/dy2J mouse, 
both presenting significant reduction of α2-laminin in the muscle and a 
severe phenotype (Vainzof, 2008).  
Feline X-linked muscular dystrophy affected cats develop marked muscle 
hypertrophy (cervical and proximal forelimb muscles). Thickening of 
tongue muscle may result in difficulties prehending food and in drooling. 
A muscular dystrophy associated with α-dystroglycan deficiency occurs in 
Sphynx and Devon Rex cats (Martin, 2008). 
 
III. Inflammatory myopathies  
 In human medicine inflammatory myopathies (IM) constitute a 
heterogeneous group of subacute, chronic or sometimes acute acquired 
muscle diseases, which have in common the infiltration of inflammatory 
cells in muscle tissue and the presence of a variable degree of clinically 
evident muscle weakness. The most common IM are: polymyositis (PM), 
dermatomyositis (DM), necrotizing autoimmune myositis (NAM) and 
sporadic inclusion body myositis (sIBM). The disorders have primarily an 
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autoimmune pathogenesis, mediated either by cytotoxic T cells, as in PM 
and sIBM, by a complement-mediated microangiopathy as in DM, or by 
macrophages and possibly autoantibodies as in NAM (Dalakas, 2011). In 
veterinary medicine inflammatory myopathies are best studied in dogs and 
horses. In dogs, the main classes of IMs in dog are masticatory muscle 
myositis (MMM), polymyositis (PM), and generalized myositis related 
with infectious causes. Extraocular myositis (EOM) is a less commonly 
occurring immune-mediated myositis. Dermatomyositis (DM) occurs in 
certain breeds and is associated with characteristic dermal and muscular 
lesions imputable to an autoimmune reaction directed against vascular 
antigens (Shelton, 2007). Necrotizing myopathies have been described in 
dogs and may be a result of many diverse causes, including inherited 
metabolic diseases and muscular dystrophies, or may be an isolated event 
following exposure to drugs, toxins and infectious agents, or hyperthermic 
episodes including malignant hyperthermia syndromes (Shelton, 2007). 
Equine inflammatory myopathies have been reviewed by Aleman in 2008 
are a result of immune-mediated and infectious causes (Alemann 2008). 
A unique tool in the histomorphological study of inflammatory myopathies 
in humans and animals is the immunohistochemical detection of Major 
Histocompatibility complex class I and II MHC class I proteins are 
essential for immune surveillance. MHC class I molecules bind CD8+ T 
lymphocytes while MHC II molecules binds CD4+ T cells. In particular 
MHC I molecules are expressed on nearly all cells, with few exceptions, 
including skeletal muscle fibers. Muscle fibers normally do not express 
detectable amounts of MHC class I or II antigens. MHC class I molecules 
are usually extensively up-regulated in inflammatory myopathies, 
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displaying an abnormal sarcolemmal as well as sarcoplasmic expression. 
From a diagnostic point of view they are extremely useful in detecting 
muscle inflammation because sarcolemmal immunolabeling can be 
observed even in areas of muscle sections remote from inflammatory 
infiltrate (Fig. I, 2). Because the MHC-I is induced in vitro by cytokines 
and chemokines such as IFN-γ or TNF-α, and several of these cytokines 
are increased in PM and sIBM muscle, it is likely that the upregulation of 
MHC-I is related to continuous overexpression of cytokines. Moreover, the 
muscle, in vivo and in vitro, has the potential to secrete pro-inflammatory 
cytokines upon cytokine stimulation in an auto-amplificatory mechanism 
that may facilitate the recruitment of activated T cells to the muscle 
contributing to the self-sustaining nature of endomysial inflammation and 
disease chronicity. 
 
Fig. I, 2: From Pacielloet al, 2009. Expression of MHC class I on muscle fibers in transversal sections that are o 
faraway from inflammatory cells. 
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In PM and sIBM there is evidence of an antigen-directed cytotoxicity 
mediated by CD8+ T cells invading MHC-I antigen expressing muscle 
fibers. Specific components include:  
1) activated, cytotoxic CD8+ T cells. The T cells invading muscle fibers 
are activated expressing MHC-I, and other adhesion molecules on their 
surface.  
2) the CD8+ cells surround healthy, but MHC-I-class expressing, non-
necrotic muscle fibers that eventually invade. The CD8/MHC-I complex is 
characteristic of sIBM and PM because it does not occur in inflammatory 
dystrophies or non-immune myopathies (Dalakas, 2001).  
3) The CD8+ T cells contain perforin and granzyme granules, which are 
vectorially directed towards the surface of the muscle fiber inducing 
necrosis upon release; further, the perforin-positive CD8+ T cells are 
autoinvasive and express costimulatory molecules. 
4) The muscle fibers can present antigenic peptides to CD8+ cells via the 
MHC-I molecule, thereby serving as antigen-presenting cells. 
5) Other immune cells support the autoimmune process in PM and sIBM 
myeloid dendritic cells, potent cells in antigen presentation, which are 
abundantly found within the endomysial infiltrates of all IM. These cells 
may present local antigens to T and B cells and contribute to muscle fiber 
injury.  
 The very first event triggering the immunological activation of 
muscle fibers and inflammatory cells in IIM is still largely unknown, but a 
possible link with infectious disease has been proposed, with several 
viruses possibly involved in chronic and acute myositis. The best evidence 
of a viral connection is with the retroviruses. Monkeys infected with the 
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simian immunodeficiency virus and humans infected with HIV and human 
T-cell lymphotropic virus develop PM or sIBM (Dalakas, 2011). Even if 
viral antigens are not detected within the muscle it is likely that virtually 
several chronic infections triggers an situ persistent inflammatory response 
with specifically activated T cells that change the local milieu leading 
finally to IIM such as sIBM. 
 With reference to this concept, a Leishmania associated 
inflammatory myopathy and cardiomyopathy with suspect autoimmune 
pathogenesis has been described by the local scientific group (Paciello, 
2009, Costagliola, 2016). This condition affects mainly the appendicular 
musculature and is often subclinical, with only a few clinical cases having 
been reported so far. Histologically, myopathic features are characterized 
by necrosis, regeneration, fibrosis and infiltration of mononuclear 
inflammatory cells. Lymphocytes, plasma cells and macrophages infiltrate 
muscle with an endomysial and perimysial distribution. The predominant 
leukocyte populations in both skeletal muscle and myocardium are CD3+, 
CD8+ and CD45RA+ with lesser numbers of CD4+ cells. Furthermore, 
only a few cells CD18+ were found mainly in the perivascular areas. Many 
muscle fibers have MHC class I and II expression at the sarcolemma. 
CD8+ T lymphocytes may invade histologically healthy muscle fibers 
expressing MHC class I antigens. No leishmanial DNA was amplified 
from the sarcoplasm of isolated muscle fibers. 
 
IV: Infectious Myopathies:  
 Pyogenic (bacterial) and Clostridial myositis are uncommon 
condition in humans, while in animals many myositis sustained by toxins 
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of Clostridial bacteria are well known. These are usually the result of 
complicated mechanical trauma or postoperative wound infection. 
Pathologically, the affected muscle initially shows acute interstitial edema, 
which is followed by a pleomorphic inflammatory infiltrate consisting first 
of neutrophyls and then lymphocytes. A variety of parasitic infections may 
involve muscle. The most common is trichinosis, which results from 
ingesting the larvae of the nematode Trichinella spiralis. 
In domestic animals a variety of parasites infects specifically muscle 
masses and are able to induce variable muscle damages (Fig. I.3).  
 
Agent  Type  Species affected  
Sarcosystis spp. Protozoan  
Horses, ruminants, pigs, 
camelids  
Trichinella spiralis  Nematode Pigs 
Neospora caninum  Protozoan  Dogs, cattle (fetal) 
Trypanosoma cruzi  Protozoan Dogs  
Cysticercus spp. Cestode (larval form) Ruminants, pigs  
Nematode larval migrans Nematode Dogs  
Hepatozoon americanum  Protozoan  Dogs  
Fig. I,3: agents of infectious myopathies  
 
V. Ischemia  
 Muscle is relatively resistant to ischemia due to its blood supply. 
Varying degrees of ischemic damage, however, may occur in human 
patients in condition such as thrombohembolism, arteriosclerosis or 
polyarteritis nodosa. The histologic changes seen in skeletal muscle 
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subjected to ischemia are not specific. The most famous ischemic 
myopathy in domestic animals is likely the so-called “deep pectroral 
myopathy” of turkey and poultry. In this disease the lesions, consisting of 
strictly focal ischemic necrosis, were confined entirely to the supra-
coracoid (deep pectoral) muscles (Siller, 1989).  
 
VI. Metabolic Myopathies  
 These are a group of diseases affecting skeletal muscle in which 
a congenital or acquired metabolic abnormality plays a predominant role in 
the pathogenesis of the lesions. In humans those condition are classified 
into 4 categories: carbohydrate metabolic disorders, disorders of the lipid 
metabolism, disorders of the mitochondrial metabolism, and disorders of 
adenine nucleotide metabolism. In veterinary medicine the most important 
diseases are those depending on defects of glycogen metabolism, and have 
been described in several breeds and species (Fig. 1.4 ). These conditions 
have the unifying feature that an abnormal accumulation of glycid-rich 
material in muscle tissue and possibly other organs cause a progressive 
dysfunction leading to different pathologic phenotypes. Equine 
polysaccharide storage myopathy (Valentine, 2003) is a presumed 
hereditary autosomal dominant myopathy due to a defect of GSY 1gene. It 
is characterized by abnormal accumulations of glycogen, glucose-6-
phosphate, and abnormal polysaccharide within type II fibers. Two types 
are described: Type 1 is associated with GYS1, while Type 2 is not 
associated with such a defect and is still diagnosed only by histological 
examination of muscle biopsies. The disease is most common in draft 
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(prevalence of >50%), warm-blood, and Quarter-Horse-related breeds. 
Ponies and miniature horses are also affected. 
 
Fig. I, 4. Comparative table of glycogenoses in human and domestic animals. 
 
VII. Endocrine Myopathies  
 Secondary muscle damage may result from hypothyroidism (less 
frequently in hyperthyroidism), hyperadrenocorticism and, in both human 
and animals. In this condition the main histological change is the selective 
type II fiber atrophy. 
 
 
 
VIII. Necrotizing myopathies causing myoglobinuria 
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 This group of diseases is characterized by injury of muscle and 
excretion of myoglobin in the urine which may lead to death. A number of 
these conditions occur sporadically and include massive trauma (crush 
injury, severe burns), toxins (alcohol, barbiturates), ischemia, excessive 
heat, exercise, electrolyte imbalance, infections, polymyositis, and 
dermatomyositis. Several hereditary disorders may also be associated with 
myoglobinuria. In malignant hyperthermia, certain genetically predisposed 
individuals may suffer, during induction of anesthesia (usually halothane 
or succinylcholine), a syndrome characterized by muscular rigidity, 
myoglobinuria, rapidly rising body temperature, metabolic acidosis, and 
circulatory collapse, which leads to death.  
 
IX. Nutritional myopathies  
 Nutritional myopathies are principally diseases of calves, lambs, 
swine and foals and goats. The most common cause is deficiency of 
selenium. Nutritional myopathy resulting from vitamin E deficiency in the 
absence of selenium deficiency is uncommon in mammals, but may be 
more common in birds and reptiles. 
 
X. Other congenital Myopathies  
 In human and domestic animals the major congenital myopathies 
include:  
1) central core disease. It is an autosomal dominant trait and is 
characterized clinically by infantile hypotonia and mild, nonprogressive 
weakness involving the proximal muscles. It is characterized by 
pathognomonic microscopical findings, revealing the presence of a 
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rounded, centrally placed "core" of myofibrillar disorganization within 
muscle fibers. Professor Paciello and colleagues described a similar 
condition in a 10-month-old, male, pony foal displaying marked 
contractures of the distal portion of the limbs (Paciello, 2006). 
2) centronuclear (myotubular) myopathy. In contrast to the other 
congenital myopathies, patients with this disorder show prominent 
involvement of extraocular and facial muscles in addition to infantile 
hypotonia and slowly progressive limb muscle weakness. Pathologically, 
the muscle shows a centrally placed nucleus in almost every fiber. This 
defect has been described in Labrador retrievers as an autosomal recessive 
defect (Blot, 2002).  
3) nemaline (rod body) myopathy. Nemaline myopathy is a nonprogressive 
illness characterized by mild weakness involving particularly the facial and 
proximal limb muscles. The pathologic hallmark of this disorder is the 
nemaline or rod body. They are dark-staining ovoid or elongated structures 
that tend to accumulate in the subsarcolemmal region of the muscle fiber. 
They are difficult to see with the H&E stain but are readily identified with 
the modified Gomori trichrome method. By electron microscopy, the rod 
bodies are seen as moderately electron-dense lattice-like structures with 
periodic lines oriented parallel and perpendicular to their long axis. They 
may be derived from disarranged Z band material. A similar myopathy has 
been described in cats (Kube, 2006). 
4) congenital fiber type disproportion. Clinically, patients with this disease 
present as floppy infants, and about half will have skeletal abnormalities, 
including congenital hip dislocation, joint contractures, foot deformities, a 
high-arched palate, and kyphoscoliosis. In general, weakness improves 
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with age. The muscle biopsy characteristically shows uniformly small 
Type I fibers, relatively large Type II fibers, and Type I fiber 
predominance. Fiber type disproportion has been observed sporadically in 
puppies affected by the “swimming puppy syndrome” (Paciello, 
unpublished).  
5) mitochondrial myopathies. A number of cases of congenital myopathy 
have been described in which the principal abnormality on muscle biopsy 
consisted in the presence of abnormal mitochondria. The specific diagnosis 
of mitochondrial myopathy should ideally be based on the combination of 
the clinical, morphologic, and biochemical information in a given case. 
These condition are poorly documented in veterinary medicine.  
6) Malignant hyperthermia (MH) is a condition that results in a sudden 
increase in myoplasmic calcium concentration leading to prolonged 
myofiber contraction and muscle rigidity, hyper- metabolism, tachycardia, 
dyspnea, metabolic acidosis, and life- threatening hyperthermia. 
Episodes are triggered by a variety of circumstances, including stress and 
pharmacologic agents such as halothane anesthesia. MH is an inherited 
disorder in humans, pigs, horses, and some dogs. The defect is in the 
ryanodine receptor (RYR1), a calcium-release channel of the sarcoplasmic 
reticulum that serves a critical role in triggering release of calcium from 
the sarcoplasmic reticulum during excitation-contraction coupling. 
 
 Our group directly contributed to the studies about animal 
models mimicking hereditary human muscle disorders in 2012 (Iovane, 
2012, unpublished data). In this work the authors described a spontaneous 
x-linked myopathy in a strain of C57/BL6 mice sharing many features of 
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X-linked myopathy with excessive autophagy (XMEA). XMEA is caused 
by VMA21 gene hypomorphic alleles resulting in an impaired lysosomal 
acidification and progressive skeletal muscle degeneration. Affected mice 
displayed increase in fiber size variation, and massive presence of large 
intracellular vacuoles containing basophilic material which was reddish at 
Engel's trichrome stain. Some vacuoles were positive for the LAMP-2 
lysosomal membrane, for autophagic markers LC3, Beclin1and P62, for 
complement membrane attack complex (C5b9). At the ultrastructural 
investigation two types of vacuoles were found, corresponding to pre-
autophagosomes and autophagolysosomes accumulations. Q-RT-PCR 
analysis revealed a significant decrease of VMA21 mRNA rate and 
confirmed this mouse strain a possible new spontaneous model for XMEA 
(Iovane, 2012, unpublished data). 
 
XI. Diseases of Neuromuscular Transmission  
 Myasthenia gravis is a disorder characterized by abnormal 
weakness and rapid fatigue of voluntary muscles. Electromyography shows 
characteristic decremental action potentials following repetitive stimulation 
of motor nerves. It is also possible to detect anti-acetylcholine receptor 
antibodies in the majority of patients with myasthenia gravis. Pathologic 
examination of the skeletal muscle in this disorder is generally not 
rewarding. The occurrence of thymic abnormalities in a high proportion of 
patients, plus the recent identification of "myoid" cells in the thymus, has 
led to the suggestion that anti-muscle antibodies might be formed in the 
thymus that may cross-react with myoneural junctions. Myastenia gravis is 
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well known in dogs and other domestic animals in concomitance or not 
with thymoma.  
 
XII. Muscle aging. 
 Sarcopenia, from the greek “poverty of flesh”, is the term used 
for the first time by Irwin Rosenberg to define the loss of muscle mass and 
strength occurring with aging (Evans, 1995). Typically, sarcopenia is a 
multifactorial condition that occurs in a variety of species and represents a 
major healthcare concern for older adults in human medicine. A lack of a 
well defined etiology is a critical barrier to developing treatments. 
Generally speaking, its pathogenesis depends on a balance between 
positive and negative regulators of muscle growth (Woo, 2017). 
 The age-related alterations in skeletal muscle are attributed to several 
factors, including neuromuscular junction, muscle structure (architecture 
and fiber composition), and metabolism (Ryall et al., 2008; Sakuma et al., 
2012). The loss of muscle mass and strength results from the progressive 
atrophy and loss of single muscle fibers, along with loss of both types of 
motor units (slow and fast). The pathogenesis of these alterations is 
associated with specific biological processes, such as oxidative stress 
(Sullivan-Gunn et al., 2013). Oxidative metabolism generates reactive 
oxygen species (ROS), which accumulate over time and are responsible for 
damaging and altering cell components, particularly mitochondria and 
DNA sequences. Several studies have demonstrated that the age-related 
reduction in the synthesis of specific muscle proteins with a concurrent 
increase in proteolysis may result in the decline of muscle protein content 
and, subsequently, of muscle mass (Proctor et al., 1998; Nair, 2005; 
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Augustin and Partridge, 2009). Skeletal muscle has four main proteolytic 
systems, namely, lysosomal, caspase, calpain and ubiquitin–proteasome, 
all of which could potentially contribute to age-related muscular atrophy.  
Animal models represent convenient and clinically relevant tools in the 
research on many human diseases. They are essential for three main 
reasons: explore the underlying pathology and molecular mechanisms of 
disorders; evaluate the potential efficacy of therapeutic interventions; and 
provide an initial estimate of the safety margin and human dosing 
parameters of a drug candidate. Rodents (mostly mouse and rat) are the 
most commonly used animal models among the vertebrate species because 
of their ease of management and handling, fast reproduction, and low 
maintenance cost. However, the use of rodents in research has some 
limitations due mostly to the challenge associated with attempting to model 
complex and still poorly understood human disorders in a lower species 
(McGonigle, 2014). Thus, it has been suggested that larger mammals may 
also be a valuable tool because their more complex anatomy and 
physiology make them more directly comparable to humans in some 
respects. Sarcopenia has been described in several animal species, from 
nematodes, flies, rodents, domestic and wild animals, and nonhuman 
primates to humans. Podolica breed, which is a dual-purpose bovine breed 
very common in the south of Italy that it is usually raised free outdoors in 
the mountains with a lifespan of about 15 years.  
Recently our group described the age-related changes of skeletal muscle in 
Podolica cows to highlight a new model of sarcopenia for comparative 
studies (Costagliola, 2016). 
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The most relevant results indicated a statistically significant positive 
association between (1) age and increasing percentage of COX-negative 
fibers,(2) age and increasing percentage of angular atrophic fibers and 
fiber-type grouping, (3) increase of sarcoplasmic deposits of b-
amyloid/AbPP and presence of lymphocytic inflammation, and (4) age and 
lymphocytic inflammation associated with MHC I sarcolemmal 
expression.  
Of special interest was the detection inflammatory changes: lymphocytic 
infiltrates were observed in 40% of samples from aged animals and MHC 
I–positive fibers in 60%. Furthermore, there was a statistically significant 
positive association between age and presence of MHC I–immunopositive 
fibers. What triggers T-cell activation in age-related bovine myositis still 
remains unclear. In human polymyositis and sIBM, there is evidence of an 
antigen-directed and MHC I–restricted cytotoxicity mediated by CD8+ T 
cells, as supported by the following: the cytotoxicity of endomysial T cells 
to autologous myotubes, the clonal expansion of autoinvasive T cells and 
the restricted usage of T-cell receptor gene families, the upregulation of 
costimulatory molecules, and the release of perforin granules by 
autoinvasive CD8 cells to lyse muscle fibers (Dalakas, 2004). Upregulated 
cytokines, chemokines, and adhesion molecules enhance the transmigration 
of T cells from the circulation to the muscle. In this work the use of 
immunohistochemical detection of MHC I in bovine myositis 
demonstrated to be an useful tool even in this species. Skeletal muscle 
atrophy was also statistically correlated with age in old animals versus 
young controls. This is a typical histologic finding of sarcopenia in all 
species. Muscle atrophy reflects a condition of unbalanced protein 
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metabolism that, in sarcopenia, has been associated with a chronic low-
grade systemic inflammation (called inflammaging) (Franceschi, 2007), 
increased levels of muscle-impairing inflammatory cytokines such as TNF-
a, age-related hormonal changes, and an imbalanced protein 
synthesis/degradation (Ryall, 2008, Sakuma, 2012). 
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1.1 Introduction: 
Equine piroplasmosis is a tick-borne protozoal disease of horses 
donkeys, mules, and zebra (DeWaal, 2004; Phipps 1996; Ribeiro 1999). 
 The etiological agents are two apicomplexan hemoprotozoa, Theileria 
equi (Mehlhorn, 1998) and Babesia caballi (Nuttall 1910), that are mainly 
transmitted by ixodid ticks. Equine piroplasmosis (EP) occurs in tropical, 
subtropical, and temperate regions, and it is maintained within equine 
populations as long as competent arthropod vectors are present 
(Boldbataar, 2005; Camacho, 2005; Gummow 1996, Ribeiro 1999, Xu, 
2003). In Italy, especially in the centralsouthern regions, EP can be 
considered endemic, and high rates of seropositive animals are reported 
(Bartolomè, 2016, Grandi, 2011, Laus, 2013, Moretti, 2010).  
Clinically, piroplasmosis can cause acute to chronic forms in adult equids 
(de Waal, 1987, Phipps, 1996, Ribeiro 1999), as well as neonatal 
syndromes and abortion in mares (de Waal, 2004; van Heerden 1996). 
With acute T. equi infection, clinical signs are usually related to marked 
hemolysis and varying degrees of thrombocytopenia, hypophosphatemia, 
anemia, and hyperbilirubinemia that coincide with high levels of 
parasitemia (de Waal, 2004, de Waal 2004).  
Chronic T. equi or B. caballi infection can present with nonspecific signs, 
including lethargy, anorexia, weight loss, and poor performance (Wise, 
2013). Anemia may be minimal or absent in equids with chronic or 
persistent infection; these animals are termed inapparent carriers, have no 
appreciable signs of disease, and are reservoirs for tick and iatrogenic 
transmission (Rothshild, 2007). Among racehorses, seropositive animals 
Inflammatory myopathy in horses with chronic piroplasmosis 
49 
 
can show decreased performance compared with seronegative horses and 
may be at risk for developing overt clinical disease or even sudden death 
(Hailat, 1997, Rothshild, 2007). 
The response of the equine immune system to piroplasms infection is 
considered complex and multifaceted (Wise, 2013). No crossprotection 
between T. equi and B. caballi is documented, as horses can be infected 
with both parasites simultaneously. A humoral response is induced and 
correlates with control of parasitemia (Cunha, 2006). The function of cell-
mediated immunity in piroplasmosis has yet to be fully determined 
(Banerjee, 1997; Wise, 2013), although it is considered essential as in other 
hemoprotozoan infections such as Babesia bovis; it is generally accepted 
that CD4+ T lymphocytes play an important role in immune defense 
against apicomplexan parasites, including Plasmodium, Toxoplasma, and 
Babesia (Frolich, 2012). Development of antierythrocyte antibodies has 
been implied in the pathogenesis of anemia in human, murine, canine, and 
bovine piroplasmosis (Adachi, 1998; Gòes, 2007). 
Causes of inflammatory myopathy in horses include bacterial 
(Actinobacillus equuli, Clostridium spp., Streptococcus equi infections) 
and parasitic (Sarcocystis fayeri) infections and immune-mediated (purpura 
hemorrhagica, idiopathic immune-mediated myositis) conditions 
(Alemann, 2008; Durward-Akhust 2016; Lewis, 2007). 
In the present study, we describe for the first time an inflammatory 
myopathy in horses affected by chronic piroplasmosis and provide insight 
into the pathogenesis. 
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1.2 Materials and methods 
1.2.1 Animals:  
The study included 16 horses, 10 females and 6 males, aged from 3 
to 28 years, referring with mild to severe clinical signs of myopathy and 
that were serologically positive by indirect fluorescent antibody test 
(IFAT) for one or both agents of piroplasmosis (cutoff of 1:80). More 
information about the animals’ signalment and clinical signs are reported 
in Table 1. Clinical signs included mild to severe muscle atrophy (Figs. 1, 
2), poor performance, fatigue, and weight loss. None of the studied animals 
showed hematologic or serum biochemical alterations consistent with acute 
piroplasmosis or clinical signs such as fever, anemia, or hemoglobinuria. 
Horses seropositive for equine herpes virus type 1 or 4 or with a clinical 
history of strangles were excluded from the study. Normal control 
specimens of equine muscle (taken from semitendinosus muscle) for 
immunohistochemical and molecular studies were selected from the 
archive of the Laboratory of Neuromuscular Pathology of the Department 
of Veterinary Medicine and Animal Production of Naples, from horses 
serologically negative for both agents of piroplasmosis and without 
histological evidence of myopathy. 
All sampling procedures from animals were performed for diagnostic 
purposes; thus, the study did not require consent or ethical approval 
according to European Directive 2010/63/EU. 
Animal sampling, including muscle biopsies, was performed by a 
veterinary surgeon (M.P.P.) after receiving the consent of the owner. Each 
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owner approved the use of tissues for research purposes, according to the 
internal rules of Diagnostic Service of the Department of Pathology and 
Animal Health of the University of Naples Federico II. 
1.2.2 Hematology and Serum Biochemistry 
Blood samples were collected from the jugular veins into vacuum 
tubes (Vacutainers; Becton Dickinson, Franklin Lakes, NJ), one with 
EDTA for complete blood count (CBC) and the other one without 
anticoagulant for serum biochemistry. Samples were sent to the laboratory 
on ice packs within 2 hours from collection, immediately centrifuged, and 
processed. CBC was performed using a cell counter analyzer (Cell Dyn 
3700; Abbott, Chicago, IL), and a complete biochemical profile (sodium, 
potassium, chloride, iron, ionized calcium, urea, creatinine, bilirubin, 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], lactate 
dehydrogenase [LDH], creatine kinase [CK], g-glutamyltranspeptidase 
[GGT], total proteins, albumin, albumin-globulin ratio, globulin) was 
performed on samples of parasitized animals using an ADVIA 1650 
Chemistry System (Siemens Healthcare, Tarrytown, NY). Serum from 2 
healthy horses that were serologically negative to both agents of EP 
protozoa were also collected. 
1.2.3 Parasitological Diagnosis 
Sera were screened at a dilution of 1:80 for antibodies against B. 
caballi and T. equi using an IFAT, according to the manufacturer’s 
instructions (Laboratory Dr. Bose GmbH, Harsum, Germany). Each 
sample was run in duplicate. Ten microliters of diluted serum was placed 
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in wells on masked slides, which contained fixed horse erythrocytes 
infected with B. caballi and T. equi. Positive and negative controls were 
supplied from the manufacturer. The slides were incubated in a humid 
chamber at 37°C for 30 minutes, successively rinsed, and soaked in buffer 
for 10 minutes. Ten micro liters of fluorescein-conjugated rabbit anti-horse 
IgG (Sigma Chemical, St Louis, MO) was applied to each well, and then 
incubation and rinse-soak steps were repeated. 
Finally, the slides were dried and mounted with 50% glycerol and 
50% carbonate-bicarbonate buffer (pH 9). The slides were observed under 
an epifluorescent microscope (DM2500; Leica, Wetzlar, Germany) using a 
xenon light source. A positive reaction appeared as peripheral clusters of 
distinct apple-green inclusion bodies within the infected erythrocytes (see 
Fig. 1.1). 
 
Fig. 1.1 IFAT results. 
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1.2.4 Histopathology and Immunohistochemistry 
Muscle biopsies from the semitendinosus muscle were collected 
and snap frozen in isopentane precooled in liquid nitrogen. 
Muscle samples from the same muscle of 5 healthy horses were used as 
control for immunohistochemical and molecular analysis. Specimens from 
both affected and control animals were frozen within 2 hours after 
sampling. Frozen sections (10 mm thick) were subjected to a standard 
panel of histochemical stains (Paciello, 2009) including hematoxylin and 
eosin (HE), Engel’s trichrome (ET), NADH-tetrazolium reductase 
(NADH-TR), succinate dehydrogenase (SDH), Cytochrome oxidase 
(COX), ATPase at pH 9.4 and 4.3, and periodic acid–Schiff (PAS) 
reaction. A scoring system was designed to assess the degree of fiber 
atrophy as follows based on assessment of 100 fibers at 200X 
magnification: mild (score 1), <10% atrophic fibers; moderate (score 2), 
10% to 50% atrophic fibers; and severe (score 3), >50% of atrophic fibers. 
A scoring system was also defined for perivascular and/or endomysial 
lymphocytic inflammation based on light microscopy: no inflammation 
(score 0); mild inflammation (score 1), 5 to 25 lymphocytes/plasma cells 
per high-power field (HPF) (400X); and moderate inflammation (score 2), 
26 to 50 lymphocytes/ plasma cells per HPF. At least 10 fields at 400X 
magnification were evaluated for each section by 2 independent 
pathologists (T.B.P. and O.P.) under an optical microscope (Nikon E600; 
Nikon, Tokyo, Japan), with a concordance rate of 95%. For 
immunohistochemistry (IHC), frozen sections (8 mm thick) were 
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processed with the MACH1 Universal HPR Polymer Detection Kit 
(Biocare Medical LLC, Concord, CA). Briefly, the sections were dried for 
1 hour at room temperature and fixed in acetone at 4C for 3 minutes; 
peroxide block was applied for 15 minutes at room temperature, and then 
the sections were incubated for 30 minutes with background sniper 
(Biocare Medical LLC). The primary antibodies were diluted in phosphate-
buffered saline (PBS) and incubated overnight at 4C. MACH1 mouse 
probe was applied for 20 minutes at room temperature. Horseradish 
peroxidase (HRP)–polymer was added for 30 minutes at room temperature. 
After every step of the procedure, the sections were washed in 0.01 M PBS 
(pH 7.2–7.4). The reaction was revealed by using 3,30- diaminobenzidine 
(DAB) chromogen diluted in DAB substrate buffer. Finally, sections were 
counterstained in Carazzi’s hematoxylin. Primary antibodies were directed 
against major histocompatibility complex I (H58A, mouse monoclonal 
antibody, dilution 1:200; VMRD, Pullman, WA), major histocompatibility 
complex II (H42A, mouse monoclonal antibody, 1:200; VMRD), CD3 
(IS503, rabbit polyclonal antibody, 1:50; Dako, Milan, Italy), CD79a 
(HM57, mouse monoclonal antibody, 1:50; Dako), CD4 (HB61A, mouse 
monoclonal antibody, 1:50; VMRD), and CD8 (HT14A, mouse 
monoclonal antibody, 1:50; VMRD). The percentage of muscle fibers with 
sarcolemmal positivity to major histocompatibility complex I and II (MHC 
I and I) was scored as follows: absent/none (score 0), 0%; mild (score 1), 
1% to 25%; and moderate (score 2), 26% to 50%. For evaluation of MHC I 
and II, fibers directly adjacent to the inflammatory infiltrate were avoided, 
since positive endomysial inflammatory cells can make evaluation of 
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sarcolemmal positivity difficult. The positive staining for MHC I and II 
varied from a continuous staining throughout the sarcolemma to a 
discontinuous sarcolemmal pattern. Endomysial blood vessels, which are 
normally positive for MHC I and II, were used as positive internal controls 
for immunohistochemistry with anti–MHC I and MHC II antibodies. 
Frozen section of normal horse lymph nodes was used as positive controls 
for immunohistochemistry with anti-CD3, CD79a, CD4, and CD8. The 
total inflammation score (IS) was obtained by summing the scores for 
lymphoplasmacytic inflammation, MHC I, and MHC II. 
1.2.5 Indirect Immunofluorescence 
To determine if IgG, IgM, or IgA autoantibodies directed against an 
unknown muscle antigen may be present in the bloodstream, we analyzed 
the serum from affected horses by using indirect immunofluorescence on 
sections of normal equine muscle (the same samples used as controls for 
histology and immunohistochemistry) as previously described in canine 
polymyositis (Hankel, 2006).  Frozen sections (8 mm thick) were dried for 
1 hour at room temperature and fixed in acetone at 4° C for 3 minutes. 
Protein block was performed using rabbit normal serum diluted 1:50 for 30 
minutes at room temperature. Then, the sera from selected affected animals 
(horse Nos. 8, 10, 13, 14, and 15) were serially diluted in PBS (undiluted, 
1:100, 1:300, 1:1000, 1:3000) and applied as primary antibody overnight at 
4C. 
Slides were then washed 3 times in PBS and incubated with a fluorescein 
isothiocyanate (FITC)–conjugated rabbit anti horse secondary antibody 
Inflammatory myopathy in horses with chronic piroplasmosis 
56 
 
(equine IgG/IgM/IgA [FITC], SA 136092; Thermo Fisher Scientific, 
Rockford, IL) diluted 1:100 in PBS for 2 hours at room temperature. Slides 
were rinsed with PBS and mounted with a solution of 1 part glycerol/ 1 
part PBS. For scanning and photography, a laser scanning microscope 
(LSM 510; Zeiss, Go¨ttingen, Germany) was used with illumination at 488 
nm and read using a 505- to 560- nm band pass filter. 
As a negative control, serial sections of muscle were incubated with PBS 
or with serum from 2 healthy horses that were serologically negative for 
piroplasms, rather than serum from affected horses. 
To determine if the presumed autoantibodies were specific for equine 
muscle, the same sera were tested on sections of normal muscle from dog, 
cat, and sheep. 
1.2.6 Reverse Transcription Quantitative Polymerase Chain 
 Reaction 
Total RNA, isolated from skeletal muscle tissue from 10 affected 
animals (horse Nos. 1–3, 6–10, 12, and 15) and 3 controls, was extracted 
using TRIzol Reagent (Invitrogen Biotechnologies, Carlsbad, CA), 
according to the manufacturer’s instructions. Cases were selected based on 
the availability of frozen material for molecular analysis. Complementary 
DNA (cDNA) was synthesized using a reverse transcription kit (Maxima 
First Strand cDNA Synthesized Kit; Fermentas, Ontario, Canada) from 2 
mg total RNA. Polymerase chain reactions (PCRs) were performed with a 
Bio-Rad CFX96 Connect Real-time PCR System instrument and software 
(Bio-Rad Laboratories, Hercules, CA). Primer and probe sequences used 
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were as follows: tumor necrosis factor (TNF)–a (F: 
TTACCGAATGCCTTCCAGTC, R: GGGCTACAGGCTTGTCACTT), 
interferon-g (IFNγ) (F: TGGACACCATCAAGG AGGAC, R: 
GGACCTTCAGATCATTTACCG), interleukin (IL)–10 (F: 
GTCATCGATTTCTGCCCTGT, R: GCTTCGT TCCCTAGGATGC), IL-
12 (F: GACGCTGTGCCTTAGC, R: 
TCTGCCTCTGAGGATCTATCAACA), IL-4 (F: CAAAA 
CGCTGAACAACCTCA, R: CTGTTGAAGCACCTTTGCAG), and IL-6 
(F: AGCAAGTGTGAAAACAGAAG, R: CAT 
CAGGCAGGTCTCCTGAT) as previously described (Ruimnaki, 2008; 
Sanchez-Matamoros, 2013). The PCR conditions were 10 minutes at 95° C 
followed by 40 cycles of 2-step PCR denaturation at 95° C for 15 seconds 
and annealing extension at 60C for 60 seconds. Each sample contained 1 to 
100 ng cDNA in 2 Power SYBRGreen PCR Master Mix (Applied 
Biosystems, Foster City, CA) and 200 nmol/l of each primer (Eurofins 
MWG Operon, Huntsville, AL) in a final volume of 25 ml. The relative 
amount of messenger RNA (mRNA) for each cytokine was normalized to 
GAPDH as a housekeeping gene, and the data were analyzed according to 
the 2–DDCT method. 
1.2.7 Reverse Transcription Quantitative PCR for T. equi and B. 
caballi DNA 
Reverse transcription quantitative PCR (RT-qPCR) for T. equi 18S and 
B. caballi was performed on 11 of 16 frozen samples of affected horses 
(horse Nos. 1–4, 6–10, 12, and 15). Cases were selected based on the 
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availability of frozen material for molecular analysis. Remaining 5 cases 
could not be evaluated due to lack of sufficient muscle tissue. Muscle 
tissue (100 mg) was disrupted in 1 ml PBS using FastPrep1 FP120 Cell 
Disrupter Instrument (Qbiogene, Montreal, Quebec) in Lysing Matrix D 
tubes (MP Biomedicals, Santa Ana, CA). DNA was extracted from 200 ml 
of the homogenized tissue (QIAcube; Qiagen, Hilden, Germany) using the 
QIAampcador Pathogen Mini Kit according to the manufacturer’s 
instructions. Each sample was extracted in duplicate, and the average 
nucleic acid concentration was measured using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). RT-qPCR 
for T. equi primers (F: Be18SF; R: Be18SR) and TaqMan probe (VIC-
TAMRA, Be 18SP) were those previously reported (Kim, 2008) and 
amplified an 81-bp fragment outside the V4 hypervariable region of the 
18S ribosomal RNA (rRNA) gene. For B. caballi, primers (F: Bc-
18SF402; R: Bc-18SR496) and TaqMan MGBTM probe (FAM-MGB, Bc-
18SP) were those reported (Bhoora, 2010) and amplified a 95-bp fragment 
in the V4 hypervariable region of the 18S rRNA gene of B. caballi. 
TaqMan Universal PCR Master Mix Kit (Applied Biosystems) was used, 
and the reactions were carried out using the ABI PRISM 7900 HT 
Sequence Detection System (Applied Biosystems). Internal positive 
controls were RT-qPCR products of B. caballi and T. equi, obtained from 
EDTA blood samples of seropositive symptomatic horses, certified by the 
Office International des Epizooties (OIE) Reference Laboratory for 
Babesiosis of the Istituto Zooprofilattico Sperimentale della Sicilia and 
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cloned in the plasmid vector PCRII-TOPO (Invitrogen). The negative 
control was RNAase-free water. 
1.2.8 Statistical Analysis 
All data were imported into a program for statistical analysis (JMP 8.0; 
SAS Institute, Cary, NC). The level of significance was set at P= .05. Data 
of cytokine mRNA levels are presented as mean+standard error of the 
mean (SEM), whose statistical analysis was performed by analysis of 
variance test for multiple comparisons followed by Bonferroni’s test, using 
GraphPad Prism (GraphPad Software, San Diego, CA). Statistical 
significance was set at P < .05. For each animal, an inflammation score 
was obtained summing the scores of lymphocytic inflammation, MHC I, 
and MHC II. Data were checked for normality of distribution with a 
Shapiro-Wilk’s W test. The relationship between IS, histological score, and 
fiber atrophy was evaluated by a Spearman rank correlation test (rs). 
1.3 Results: 
1.3.1 Parasitological Diagnosis, Hematology, and Serum 
Biochemistry 
Signalment, clinical signs, selected serum biochemical findings, and 
serologic titers are provided in Table 1. By IFAT, 10 of 16 horses were 
positive for serum antibodies against both parasites, 3 of 16 were positive 
for B. caballi, and 3 of 16 were positive for T. equi (see Table 1). 
Hematocrit was lower than 0.3 in 5 of 16 horses. The mean corpuscular 
volume (MCV) was lower than 45 fl in 2 of 16 horses. White blood cell 
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(WBC) count was higher than 9.5 109/L in 2 of 16 horses, and in 11 of 16, 
platelets were lower than 1.6 1011/L. In 11 of 16 horses, b1-globulins were 
above the normal range (30–110 g/l), and albumin was 
reduced (<45 g/L) in 2 of 16 horses. In 3 of 16 horses, raised levels of 
serum bilirubin (>50 mmol/l) were observed. In 2 of 16 horses, 
hemoglobin (Hb) was lower than normal range (<68.3 mmol/L). 
 
case 
number breed sex 
age 
(years) Clinical Signs 
CK 
(U/l) 
LDH 
(UIl) 
AST 
(U/L) T. equi 
B. 
caballi 
#1  
Italian 
Saddle 
Horse  
F  18  muscle atrophy, poor 
performance, weight loss  
414  1072  696  -  1:80  
#2  
Sardinian 
Anglo-arab  
NM  21  
mild muscle atrophy, poor 
performance, weight loss, muscle 
fatigue  
314  448  417  -  1:80  
#3  
Italian 
Trotter  
F  6  
moderate muscle atrophy, weight 
loss  
183  495  249  1:80  1:80  
#4  
Appaloosa  F  12  
moderate muscle atrophy, poor 
performance, muscle fatigue  
96  339  226  1:320  1:640  
#5  
Italian 
Trotter  
F  25  
moderate muscle atrophy, weight 
loss  
185  713  306  1:1280  -  
#6  
Italian 
Trotter  
F  3  
severe muscle atrophy, poor 
performance, weight loss, muscle 
fatigue  
76  313  264  -  1:80  
#7  
Italian 
Trotter  
M  3  
moderate muscle atrophy, poor 
performance, weight loss, muscle 
fatigue  
62  309  215  1:320  1:640  
#8  
Italian 
Trotter  
M  20  
moderate muscle atrophy, muscle 
fatigue, weight loss  
180  610  210  1:2560  1:320  
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case 
number breed sex 
age 
(years) Clinical Signs 
CK 
(U/l) 
LDH 
(UIl) 
AST 
(U/L) T. equi 
B. 
caballi 
#9  
Italian 
Saddle 
Horse  
F  21  moderate muscle atrophy, weight 
loss  
148  773  313  1:1280  -  
#10  
Mixed 
Quarter 
Horse  
F  15  moderate muscle atrophy, poor 
performance  
198  630  381  1:1280  1:80  
#11  
Quarter 
Horse  
F  5  
moderate muscle atrophy, poor 
performance,  
159  588  213  80  1:160  
#12  Appaloosa  NM  12  mild muscle atrophy  112  439  230  2560  1:80  
#13  
Pony  F  24  
mild muscle atrophy, poor 
performance, weight loss  
*  *  *  1:1280  1:80  
#14  
Mixed 
Quarter 
Horse  
NM  21  mild muscle atrophy, poor 
performance  
130  347  206  1:2560  1:80  
#15  
Italian 
Trotter  
M  28  
moderate muscle atrophy, poor 
performance, weight loss  
140  441  220  1:80  1:160  
#16  
Italian 
Trotter  
F  14  
moderate muscle atrophy, weight 
loss  
238  578  239  1:320  -  
Table .11: Signalment, muscle enzymes and IFAT titre. 
 
Hematocrit was lower than 0.3 in 5 of 16 horses. The mean corpuscular 
volume (MCV) was lower than 45 fl in 2 of 16 horses. White blood cell 
(WBC) count was higher than 9.5 109/L in 2 of 16 horses, and in 11 of 16, 
platelets were lower than 1.6 1011/L. In 11 of 16 horses, b1-globulins were 
above the normal range (30–110 g/l), and albumin was reduced (<45 g/L) 
in 2 of 16 horses. In 3 of 16 horses, raised levels of serum bilirubin (>50 
mmol/l) were observed. In 2 of 16 horses, hemoglobin (Hb) was lower than 
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normal range (<68.3 mmol/L). Serum activity of CK was mildly elevated 
in 10 of 16 horses, AST in 5 of 16, and LDH in 8 of 16 (Table 1), and SDH 
and g-glutamyltransferase (g-GT) were both elevated (>4 IU and 35 IU, 
respectively) in 1 of 16. Those minor serum biochemical abnormalities 
were consistent with a chronic form of equine piroplasmosis. 
1.3.2 Histopathology and Immunohistochemistry 
Pathological changes in muscle from all affected horses were 
similar, although they varied in severity (Table 1.2).  
Case 
numbe
r 
Atroph
y 
score 
Lymphocyti
c 
inflammatio
n 
distribution 
of 
inflammatio
n 
CD
3 
CD
4 
CD
8 
CD79
α 
MH
C I 
MH
C II 
IS
* 
#1 3 1 perivascular 2 1 1 0 2 1 4 
#2 1 0 - 0 0 0 0 0 0 0 
#3 2 0 - 0 0 0 0 1 1 3 
#4 2 1 perivascular 1 0 2 1 1 1 5 
#5 2 2 perivascular 2 2 1 1 1 1 5 
#6 2 1 perivascular 1 1 1 1 1 1 5 
#7 2 1 
perivascular 
and 
endomysial 
1 1 1 1 1 1 4 
#8 2 2 perivascular 2 2 2 1 1 1 5 
#9 2 1 perivascular 1 1 1 1 1 1 3 
#10 2 1 perivascular 1 1 2 1 1 1 3 
#11 2 1 perivascular 1 1 1 0 1 1 3 
#12 1 1 perivascular 1 2 1 1 1 1 3 
#13 1 1 
perivascular 
and 
endomysial 
1 1 1 1 1 1 3 
#14 1 0 - 0 0 0 0 1 1 3 
#15 2 1 endomysial 1 1 0 0 1 2 4 
#16 2 1 perivascular 1 1 1 0 1 1 4 
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Table 1.2 Histological findings. 
In 11 of 16 cases (94%), the muscle contained small lymphocytes with 
fewer macrophages, plasma cells, and rare eosinophils (Figs. 1.2, C). 
In 12 of 16 cases, lymphocytic infiltrate formed cuffs around perimysial 
and endomysial blood vessels (perivasculitis; Fig. 1.2, C) with small 
numbers of lymphocytes scattered in the endomysium; 3 of 16 cases had 
mild lesions only in the endomysium. Only in 1 case with evident 
inflammation perivascular cuffing was not observed. In addition to 
lymphocytes, macrophages were also present in 5 of 16 cases (31%) (Fig. 
1.2 E). Various degrees of nonangular fiber atrophy was observed (Table 
1.2), scored as mild in 4 of 16 cases (25%), moderate in 11 of 16 cases 
(69%), and severe in 1 case (6%). No fiber type selectivity was detected by 
ATPase staining at pH 9.4 and 4.3 (Fig. 1.2, E). Furthermore, 
mitochondrial abnormalities were identified using histoenzymatic stains in 
13 of 16 cases (82%), including ragged blue fibers with SDH (Fig. 1.2, G) 
and fibers with a moth-eaten appearance with COX (Fig. 1.2, H) and 
NADH stains. Importantly, mitochondrial alterations were more prominent 
in muscle fibers adjacent to inflammatory infiltrates (Fig. 1.2, H). 
Additional morphological findings were as follows: necrotic fibers 
associated with sarcoclastosis (phagocytes invading necrotic fibers) in 11 
of 16 cases (69%); hypereosinophilic, round, and swollen degenerated 
fibers in 12 of 16 cases (75%) (Fig. 1.2, D); and mild perimysial fibrosis in 
5 of 16 cases (31%). No parasites or PAS-positive accumulations related to 
polysaccharide storage myopathy were found. The control biopsies did not 
contain histologic lesions or abnormalities in serum CK, LDH, or AST. 
Inflammatory myopathy in horses with chronic piroplasmosis 
64 
 
The immunophenotype of inflammatory cells in skeletal muscle was 
identified by immunohistochemistry. All cases contained CD3+ T-cell 
populations with CD4+ and CD8+ equally represented in 7 of 16 cases 
(43.7%; Fig. 1.3 B, C). Only in 2 cases (horse Nos. 5 and 12) were CD4+ 
lymphocytes more abundant than CD8+. Scattered CD79a+ cells were 
present in 9 of 16 cases (56%), especially where the degree of 
inflammatory change was more severe. Lymphocytic infiltrate was graded 
as follows (Table 1.2): mild (score 1) in 11 of 16 (69%), severe (score 2) in 
2 cases (13%), and absent (score 0) in 3 cases (19%). Furthermore, we 
evaluated the expression of MHC I and II antigens in myocytes. As 
expected, endothelial cells were positive in sections both from control and 
affected animals (Fig. 1.3 E- H) as well as many inflammatory cells (not 
shown). The majority of biopsies from affected animals (11/16 cases; 94%) 
showed a mild (score 1, 14/16 cases; 88%) to moderate (score 2, 2/16 
cases; 13%) immunoreactivity to MHC I and II (Fig. 1.3 E, F). The 
staining pattern was localized to the sarcolemma or the cytoplasm 
(sarcoplasm) in both the atrophic and normalsized fibers. The staining 
pattern varied from a distinct, continuous sarcolemmal positivity, to 
discontinuous sarcolemmal positivity, to sarcoplasmic positive spots. 
Positive muscle fibers were even found distant from the inflammatory 
infiltrate. In control cases, MHC I and II expression was restricted to 
endothelial cells (Fig. 1.3, G, H). The histopathologic data were analyzed, 
and a statistically significant correlation between inflammation and atrophy 
scores was found (rs= 0.6; P = .02, Spearman rank correlation test). The 
atrophy and MHC I scores were also correlated (rs = 0.6; P = .008). No 
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correlation was found between inflammation score and serum levels of 
muscular enzymes (CK, P = .24; LDH, P = .8; AST, P = .53) or between 
inflammation score and serum titers to etiological agents (T. equi, P = .09; 
B. caballi, P = .86; T. equi and B. caballi, P = .22). 
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Figure 1.2. Myositis associated with chronic piroplasmosis, histology results, horse. A Horse No. 7. Moderate 
atrophy of hindlimb muscles. B Horse No. 1. Severe atrophy of hindlimb muscles. C Horse No. 5. Perivascular, 
perimysial, and endomysial accumulation of lymphocytes and plasma cells. Hematoxylin and eosin (HE). D 
Horse No. 8. Moderate variability in fiber size with mainly nonangular atrophic fibers, a swollen 
hypereosinophilic degenerated fiber, and a necrotic fiber invaded by phagocytes (sarcoclastosis). HE. E Horse 
No. 5. Perivascular aggregates of esterase-positive macrophages. Nonspecific esterase stain. F Horse No. 7. 
Atrophic muscle fibers of both fiber type. ATPase stain pH 9.4. Type II fibers are dark; type I are light. G. Horse 
No. 10. Ragged blue fibers. Succinic dehydrogenase stain. H. Horse No. 6. Several moth-eaten fibers, especially 
near the perivascular inflammatory infiltrate (asterisk). Cytochrome oxidase stain. 
Inflammatory myopathy in horses with chronic piroplasmosis 
67 
 
 
Figures 1.3. Myositis associated with chronic piroplasmosis, immunohistochemistry, horse. A. Horse No. 4. 
Perivascular lymphocytes are mainly (B) CD3+ T cells with fewer (A) CD79+ B cells. Immunoperoxidase, 3,30-
diaminobenzidine chromogen. B. Horse No. 5. Equal proportions of (a) CD4+ and (b) CD8+ T lymphocytes. 
Immunoperoxidase, 3,30-diaminobenzidine chromogen. C. Horse No. 1. Abnormal sarcolemmal staining for 
major histocompatibility complex (MHC) class I (arrow) scored as 2. Immunoperoxidase, 3,30-
diaminobenzidine chromogen. D. Horse No. 15. Abnormal sarcolemmal staining for MHC II  scored as 2. 
Immunoperoxidase, 3,30-diaminobenzidine chromogen. E, F Skeletal muscle, horse, normal control. Absence of 
staining for MHC I (G) and MHC II (H). Only endomysial blood vessels are positive. Immunoperoxidase, 3,30-
diaminobenzidine chromogen. 
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1.3.3 Indirect Immunofluorescence 
To detect muscle-specific antibodies in serum of affected horses, 
serum was applied to sections of muscle and then probed with antibody 
against equine IgG, IgM, and IgA. Distinct sarcolemmal labeling was 
detected in all sections subjected to serum from 4 affected animals even at 
high dilution (1:3000) of the conjugate (Fig. 1.4, A). Sections incubated 
with serially diluted serum from normal control horses did not show the 
same dilution-dependent fluorescence pattern (Fig. 1.4, B). Weak 
sarcolemmal staining was detected in sections incubated with serum from 
normal control horses and interpreted as nonspecific background, because 
its intensity did not vary significantly at different dilutions, whereas the 
labeling was dilution dependent for sections incubated with serum from 
affected horses. No staining was observed in sections incubated with PBS 
rather than equine serum (Fig. 1.4, A,B) or sections treated with PBS rather 
than FITC-conjugated secondary antibody (not shown). 
To investigate species specificity of the target antigens, equine serum was 
applied to sections of skeletal muscle from dog, cat, and sheep and 
detected as above. Using serum from affected horses, antibodies bound to 
dog, cat, and sheep skeletal muscle cryosections, with similar staining 
intensity (Fig. 15, A). In contrast, normal control horse serum showed no 
immunolabeling of muscle from these species (Fig. 15, B). 
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Figure 1.4. Control equine muscle cryosections stained with undiluted and serially diluted serum from horse 
No.14 (A) and serum from a normal healthy horse (B). Strong, dilution dependent, sarcolemmal positivity is 
evident only on sections treated with serum from affected horse (A); sections treated with PBS rather than serum 
are also negative (A and B). Indirect immunofluorescence, FITC-conjugated rabbit anti-horse IgG. 
 
Figure 1.5. Normal canine, feline and sheep muscle cryosections stained with serum from horse No.14 diluted 
1:300 (A) and serum from a normal healthy horse (B) and a FITC-conjugated rabbit anti-horse IgG, IgM, IGA. 
Strong sarcolemmal positivity is evident only on sections treated with serum from affected horse (A); sections 
treated with control serum are negative (B). Indirect immunofluorescence. 
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1.3.4 Molecular Findings 
Using RT-qPCR, significantly increased mRNA levels of IL- 12, 
TNF-α, and IFN-γ were found in muscle samples from affected animals 
compared to controls, while IL-10 mRNA levels were not different 
between affected and control animals (Fig. 1.6). No amplification of IL-4 
and IL-6 was found either in specimens from affected animals or controls. 
T. equi and B. caballi DNA was not detected by RT-qPCR in any of the 11 
muscle samples tested from horses with chronic piroplasmosis. 
 
 
Figure 1.6. Analysis of (a) tumor necrosis factor (TNF)–α, (b) interleukin (IL)–10, (c) IL-12, and 
(d) interferon-g (IFN-γ) gene expression based on reverse transcription quantitative polymerase 
chain reaction, from skeletal muscle of horses with myositis associated with chronic piroplasmosis 
compared to healthy controls. Data are mean + SD of 5 samples per group. *P < .05 vs control. 
mRNA, messenger RNA. 
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1.4 Discussion: 
Although clinical evidence of muscle impairment has been reported in 
chronic equine piroplasmosis (Wise, 2013) the histopathological and 
immunological features have not been documented to date. This study 
provides the first evidence of muscle pathology in horses chronically 
affected by piroplasmosis and with a clinical history of muscle atrophy and 
poor performance. Our results suggest that in chronic equine 
piroplasmosis, functionally important muscle damage may depend on an 
immune-mediated muscle damage involving circulating autoantibodies, 
and local cytokine expression may contribute to impaired muscle function. 
If so, this common protozoal disease should be included in the differential 
diagnosis of polymyositis and poor performance in horses as well as one of 
the possible causes underlying equine immune-mediated myopathy. Our 
work highlights the importance of the histopathological evaluation of 
muscle biopsies as a starting point for a more precise understanding of the 
pathogenesis of clinical signs of muscle impairment. 
To date, histopathological features and pathogenetic aspects of idiopathic 
inflammatory myopathies have been extensively studied, especially in 
humans and dogs (Dalakas, 1996; Dalakas, 2011, Evans, 2004, 
Ghiraredello, 2013; Grundtmann, 2007; Lundberg, 1995; Pumarola, 2004; 
Vattemi, 2014). In humans, the main idiopathic inflammatory myopathies 
are polymyositis (PM), dermatomyositis (DM), immune-mediated 
necrotizing myopathy (NM), and sporadic inclusion body myositis (sIBM) 
(Dalakas, 2011). The disorders have primarily an autoimmune 
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pathogenesis, mediated either by cytotoxic T cells, as in polymyositis and 
inclusion body myositis; by a complement mediated microangiopathy, as 
in DM (dermatomyositis); or by macrophages and possibly autoantibodies, 
as in NM (necrotizing myopathy) (Dalakas, 2011). In dogs, the best-known 
immune-mediated myopathies are masticatory muscle myositis (Wu, 
2007), polymyositis, dermatomyositis, extraocular muscles myositis (Jubb, 
2015) and inflammatory myopathy associated with Leishmania infantum 
infection (Paciello, 2009). Masticatory muscle myositis and extraocular 
muscle myositis involve an immune response directed against unique 
antigens of this muscle group, while polymyositis and dermatomyositis 
share many pathogenetic aspects with their human counterparts (Evans, 
2004; Pumarola, 2004). Systemic infectious diseases have been proposed 
as triggering factors of inflammatory myopathies and cardiomyopathies in 
humans, dogs, and hamsters (Costagliola, 2016, Dalakas, 2011; Evans, 
2004, Iwai, 2005; Paciello, 2010). At least 3 main mechanisms have been 
proposed to explain the role of infectious factors as a trigger for 
autoimmune disease involving skeletal muscles: (1) polyclonal B- or T-cell 
activation, (2) molecular mimicry, or (3) immunogenicity of muscle auto-
antigens secondary to infection-mediated inflammation (Bach, 1998; 
Fujinami, 1989; Sakkar, 2008).  
Based on anamnestic and histopathological data, we described an equine 
inflammatory myopathy that seems to involve an immune-mediated 
pathogenesis. A similar pattern of cellular infiltration has been described in 
equine immunemediated myositis, (Dirward-Akurst, 2016; Lewis, 2007) 
with the only exception that CD4+ cells were the predominant lymphocyte 
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in immune-mediated myositis but were rare in the myopathy associated 
with chronic piroplasmosis (only 2 of 16 cases). Given the perivascular 
pattern of the mixed T-lymphocytic infiltrate (CD4+ and CD8+ cells), we 
cannot exclude an immune reaction against blood vessels as the primary 
target as in human and canine dermatomyositis (Bach, 1998; Fujinami, 
1989). However, the absence of a true vasculitis (ie, inflammatory cells 
invading and causing damage to vessel walls) and binding of serum 
antibodies to myocytes identified by indirect immunofluorescence are 
findings that argue against an immune reaction against blood vessels. A 
more likely explanation for the inflammatory myopathy caused by 
piroplasmosis seems to be an immune reaction to a protozoal antigen 
priming molecular mimicry, with subsequent development of 
autoantibodies against muscle antigens that result in damage to myocytes.  
Recently, in another project from our group, the same hypothesis 
has been tested in canine polymyositis associated to Leishmania infantum 
(Prisco et al., unpublished data 2017). In particular, indirect 
immunofluorescence using sera from leishmania infected dogs has been 
performed, and gave similar results form the present study (dose dependent 
sarcolemmal positivity on muscle sections from normal skeletal muscle of 
dog, sheep and mouse). As further experiment, the author performed 
immunoblot analysis using the same sera and normal muscle proteins 
extract to check the molecular weight of the unknow antigen(s). A band to 
about 120 kDa was identified in all immunoblot experiments using the sera 
positive to immunofluorescence. This 120 kDa protein (p120) was not 
detected in muscle extracts using the sera of normal dogs. 
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The sarcolemmal upregulation of MHC I, the presence of cytotoxic 
CD8+ T lymphocytes that are the histological hallmark of human and 
canine PM (polimyositis) (Dalakas, 2011, Das, 2013; Evans, 2004), and 
the presence of sarcolemmal staining following incubation with infected 
horse sera all support this hypothesis. Moreover, the similar findings when 
serum of infected horses was incubated with muscle tissue from 3 other 
species (dog, cat, and sheep) make it likely that such autoantibodies are not 
species specific, resembling autoantibodies in canine PM (Hankel, 2006). 
In this study, we did not examine binding of serum antibodies to other 
normal tissues to determine if equine piroplasmosis autoantibodies are 
muscle specific. 
Regarding the immunohistochemical detection of sarcolemmal MHC I and 
II, it is noteworthy that MHC upregulation has been found in immune-
mediated idiopathic myositis. The diagnostic value of detection of 
sarcolemmal MHC I and II in human and canine inflammatory myopathies 
(Paciello, 2009; Paciello, 2007; van der Pas, 2004); has been recently 
confirmed in equine immune-mediated myositis (Durward-Akhurst, 2016). 
Upregulation of MHC I and II has been correlated to the active role of 
muscle fibers in antigen presentation and in initiating and maintaining 
pathological events in myositis independently of inflammatory infiltrates 
(Englund, 2001; Paciello, 2007) it is conceivable to speculate that during 
chronic piroplasmosis, an unknown stimulus could activate a series of 
inflammatory pathways resulting in sarcolemmal overexpression of MHC I 
and II, which in turn would attract T lymphocytes that exacerbate and 
perpetuate the inflammatory myopathy. 
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RT-qPCR for direct identification of piroplasmal DNA in skeletal muscle 
gave negative results in our study. Like in other immune-mediated 
myopathies (Dalakas, 2011), chronic infections do not cause muscle 
damage through a direct replication of the agent in the muscle but instead 
trigger a persistent inflammatory response with activated T cells. Indeed, in 
humans and monkeys infected with human immunodeficiency virus that 
develop PM or sIBM (sporadic Inclusion Body Myositis), sensitive PCR 
studies have repeatedly failed to confirm the presence of the virus in 
muscle (Dalakas, 1986a, Dalakas, 1986b; Leon-Monzon, 1993). Further 
studies are needed to definitely establish a direct link between chronic 
piroplasmosis and immunemediated myositis, such as the identification of 
clonally activated T lymphocytes stimulated by piroplasm antigens. For the 
inflammatory cytokines IL-12, TNF-α, and IFN-γ, the levels of gene 
expression within muscle were increased in affected compared to control 
animals. IL-12 is a proinflammatory cytokine produced by both immune 
and nonimmune cells (Mosaad, 2003; Temblay, 2007) that play a key role 
in autoimmune diseases and food allergies (Temblat, 2007). Indeed, it 
stimulates the production of IFN-γ and TNF-α from Th1 cells and natural 
killer (NK) cells, respectively. TNF-α (also named cachectin) is involved 
in the pathogenesis of muscle wasting in human sarcopenia and cachexia 
(Hall, 2011) TNF-α effects are mediated by the transcription factor nuclear 
factor (NF)–kB, which upregulates the ubiquitin-proteasome pathway and 
increases the expression of inducible nitric oxide synthase (iNOS), leading 
to oxidative stress (Hall, 2011, Li, 2000) and decreased protein content in 
muscle fibers. In horses, TNF-α was demonstrated to stimulate granulocyte 
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diapedesis and their adherence to the endothelium (Bailey, 2001). Notably, 
TNF-α is able to antagonize the biological effects of insulinlike growth 
factor 1 (Frost, 2003), thus contributing to the development of muscle 
atrophy. TNF-α has a synergistic role with IFN-g in inducing muscle 
atrophy in human muscle cell culture and animal models of cachexia 
(Kalovidouris, 1995; Matthys, 1991) TNF-a and IFN-g are also considered 
strong inducers of MHC I antigens on muscle. Furthermore, previous 
studies demonstrate that cytokine stimulation induces muscle fibers to also 
secrete proinflammatory cytokines, such as IFN-γ, in an autoamplificatory 
mechanism that may facilitate the recruitment of activated T cells 
contributing to the self-sustaining nature of myositis and disease chronicity 
(Figarella-Branger, 2003; Lundberg, 1995) TNF-α, IFN-γ, and IL-12 are 
indicative of a typical Th1-mediated response (Kumar, 2009), and their 
involvement in the immune response in equine piroplasmosis (Hanafusa, 
1998) could explain the prominent muscle atrophy in our cases considering 
their aforementioned biological function. Furthermore, a statistically 
significant correlation between inflammation score and muscle atrophy 
was found, suggesting a common pathogenic mechanism related to the 
chronic release of cytokines such as TNF-α or IFN-γ. Cytokines have been 
demonstrated to be a promising immunotherapeutic target (De Paepe, 
2015; Ohsugi, 2007).  
Mitochondrial abnormalities are frequently associated with muscle 
inflammation, as reported in several human inflammatory myopathies 
where they are generally associated with damage to the mitochondrial 
DNA (Oldfors, 2006; Varadhachari, 2010). In 82% of muscle biopsies 
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from affected horses, prominent mitochondrial histochemical alterations 
were found, possibly contributing to clinical muscle impairment. In 
conclusion, we described a clinically significant inflammatory myopathy 
associated with chronic equine piroplasmosis. The condition is 
characterized by infiltration of CD4+ and CD8+ T lymphocytes, evidence 
of binding of serum antibodies to muscle antigens, and increased gene 
expression of inflammatory cytokines, suggesting a likely immune-
mediated pathogenesis. 
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Chapter 2 
Lymphoplasmacytic myositis and expression of 
Major Histocompatibility Complex class I in ovine 
muscular sarcocystosis  
 
 
 
 
 
 
 
 
 
 
Based on: Lymphoplasmacytic myositis and sarcolemmal expression of Major 
Histocompatibility Complex class I and II associated with muscular sarcocystosis in 
sheep. Pagano TB, Costagliola A, De Biase D, Rinaldi L, Cringoli G, Bosco A, 
Papparella S, Paciello O. XII Convegno AIPVet Perugia, 15-17 Giugno 2015. 
Lymphoplasmacytic myositis and expression of MHC I in ovine muscular sarcocystosis 
 
85 
 
2.1 Introduction 
Sarcocystosis (syn. Sarcosporidiosis) is a protozoal disease affecting a 
wide range of animals, including mammals, reptile and birds. The 
etiological agents are more than 130 species of Sarcocystis, an intracellular 
protozoan parasite classified in the phylum Apicomplexa (class 
Conoidasida, order Eucoccidiorida, family Sarcocystidae, genus 
Sarcocystis (from the old Greek: sarx = flesh and kystis = bladder (Levine, 
1986). 
Miescher in 1843 first reported white threadlike cysts in striated 
muscles of a house mouse, that’s why, for the following 20 years, the 
parasite was simply referred to as “Meischer’s tubules”. In the following 
decades similar structures were found in other species, and the parasite was 
then re-named Sarcocystis meischeriana (Dubey, 1989). Scientists debated 
for a long time whether Sarcocystis species were protozoa or fungi, but it 
was not until 1967, after several studies at electron microscopy, that 
Sarcocystis was included in other apicomplexan protozoa such as 
Toxoplasma and Eimeria (Senaud, 1967).  
In 1979 Rommel and colleagues reported that Sarcocystis underwent a 
coccidian-like indirect lifecycle cycle with each species having an 
obligatory two-host predator-prey lifecycle (Rommel et al., 1979): the 
definitive host(s) is usually a carnivore and the intermediate host(s) is 
usually an herbivore or an omnivore (Fig. 2.1). Infections are recognized to 
occur in all parts of the world and farm animals are intermediate hosts for a 
wide number of species. 
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Intermediate hosts become infected following ingestion of sporocysts 
released by the definitive host. Following excystation in the intestinal 
lumen, sporozoites penetrate the gut wall and multiply asexually by two 
schizogonous cycles in endothelial cells of blood vessels (first and second 
generation merogony), with an associated parasitaemia. The merozoites 
released after second generation merogony penetrate muscle cells and form 
characteristic sarcocysts filled with bradyzoites, although they may also 
invade the central nervous system (Rommel, 1985). Ingestion of infected 
muscle by the definitive host triggers a sexual life cycle in the intestine 
lining with the formation of macro- and microgamonts leading to the 
development of oocysts and then sporocysts which are excreted in the 
faeces (Bruxton, 1998, Fayer, 2004). 
  Sheep are the intermediate host for four species, two microcyst 
species (S. tenella [syn. S. ovicanis] and S. arieticanis) and two macrocyst 
species (S. gigantea [syn. S. ovifelis] and S. medusiformis) (Bruxton, 1998).  
The prevalence of muscular sarcocystosis in sheep and other ruminants is 
worldwide extremely high and virtually close to 100% (O’Donoghue, 
1986, Meistro et al., 2015, Vangeel et al., 2007, Chiesa et al., 2013). 
 
Fig. 2.1 Sarcocystis spp. lifecycle (modified from Bruxton et al., 1998) 
Lymphoplasmacytic myositis and expression of MHC I in ovine muscular sarcocystosis 
 
87 
 
However, a great geographical variation in the prevalence of infection has 
been reported, with highest percentages in Asia compared, for instance, to 
North America.  
The definitive hosts are carnivores, including dogs, cats, mammalian 
wildlife, birds, reptiles and humans. The specific host varies with the 
species of Sarcocystis. In Table 2.1, the more known species of Sarcocystis 
in domestic animals with relative definitive and intermediate hosts are 
presented.  
Intermediate host Species Definitive host 
Cattle  S. cruzi  Dog, Wolves, coyotes, 
raccoons, foxes and 
hyenas 
 S. hirsuta  Cat  
 S .hominis Human, Non human 
primates 
(buffalo)  S. fusiformis  Cat  
Horse  S. fayeri  Dog  
 S. bertrami  Dog  
Sheep  S. gigantea  Cat  
 S. medusiformis  Cat  
 S. tenella  Dog  
 S. arieticans  Dog  
Goat  S. capricanis  Dog  
 S. hericanis  Dog 
 S. moulei Dog 
Swine  S. porcihominis  Human , Non human 
Primates 
 S.porcifelis  Cat  
 S. meisheriana Dog 
Table 2.1: Sarcocystis in domestic species. 
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Sarcocystis spp. are genetically programmed to complete their life 
cycles in specific intermediate hosts or within closely related host species. 
For example, sporocysts of S. hominis infect cattle but not pigs whereas 
those of S. suihominis infect pigs but not cattle (Fayer, 2004). 
Within the muscle fiber, mature banana-shaped bradyzoites reside 
within a specialized structure called parasitophorous vacuole (PV). The 
structure of the sarcosyst wall is the most important feature used in species 
identification. Based on examinations by transmission electron microscopy 
(TEM) Dubey identified 24 basic types (Dubey et al., 1989).  
 
Fig 2.2: Transmission electron micrograph of a transversally sectioned sarcocyst from Ovis musimon showing 
groups of bradyzoites separated by thin septa (5) of ground substance and the palisade-like projections of the 
primary cyst wall (PCW). Hc, host cell; Me, Metrocyte; Mn, Micronemes; A, Amylopectin granules. From Nigro 
et al. 1991. 
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The wall may be relatively simple, consisting of only minor modifications 
of the parasitophorous vacuole (PV) membrane to form the primary cyst 
wall (PCW). However, in some species the PCW is highly complex and 
contains branches, folding and villar protrusions that result from 
microtubules, microfilaments and electrondense bodies/granules that may 
modify with the age of the cyst. The PCW is immediately under-layed by 
electron dense ground substance arranged in septa that usually divide 
groups of bradyzoites in different compartments. A secondary cyst wall is 
rarely present (i.e. S. gigantea in sheep) and is composed of fibrillar 
material of host cell origin that encloses the parasitized myocytes (Lindsay 
1995). 
Relatively little is known of the immunity induced by infection with 
Sarcocystis spp. but research indicates that protective immunity does 
develop and that cell-mediated mechanisms are probably important. It 
seems likely that Sarcocystis spp. stimulate immune mechanisms similar to 
those induced by T. gondii and N. caninum. Immunity to one species does 
not appear to trigger protective immunity to another species (Fayer and 
Dubey 1984). 
The consequences of sarcocysts’s infection are extremely different 
depending on the host (definitive, intermediate or accidental) and on the 
stage of disease.  
In intermediate hosts, like sheep, the infection is mostly asymptomatic, and 
the presence of muscular cysts is considered an incidental finding 
occurring in virtually all (close to 100%) production ruminants. 
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However, even in sheep some species of Sarcocystis, particularly those 
with a canine definitive host, may cause clinical symptoms including fever, 
inappetence and reduced productivity (Uggla and Buxton, 1990).  
Fayer and Elsasser (1991) explained those symptoms with the release of 
interleukin-1 (IL-1), prostaglandin E2 (causing fever) and tumor necrosis 
factor-alpha (TNF-α), which is released by macrophages infected by 
Sarcocyst suites and causes inappetence, anemia and suppression of the 
release of pituitary growth hormone (GH), with resultant weight loss. Less 
frequently, abortion and stillbirths (Uggla and Buxton, 1990) or central 
nervous signs, including acute myopathy, ataxia, paresis and death (Jeffrey 
et al., 1988; Dubey et al., 1989; O’Toole et al., 1993) have been associated 
with sarcocystosis. Acute syndrome (named Dalmeny disease) is 
associated with the 2 phases of schizogony within endothelial cells of 
small blood vessels (Buxton et al., 1998). Apparently, the severity of 
clinical symptoms is dose dependant in experimental disease (Rommel, 
1985) and pregnant sheep infected with high doses of S. tenella gave birth 
early to small, weak lambs and developed myositis, myocarditis and 
encephalitis after parturition (Munday, 1981). 
In general, in muscular sarcocystosis, most available literature 
reports only little lymphocytic endomysial infiltrate accompanied by mild 
degenerative muscle fiber changes (hyaline or floccular degeneration) in 
appropriate intermediate hosts. On pathology textbooks is reported that the 
extent of muscle change bears little relationship to the numbers of 
developing cysts, but generally, very low numbers of Sarcocystis produce 
no reaction. As cysts mature, and the contained bradyzoites become more 
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distinct, the cyst capsule within the enlarged muscle fiber becomes thicker 
and more clearly differentiated from the muscle sarcoplasm. In some 
parasitic species, the outer capsular zone develops distinct radial striations, 
which, on electron microscopy, prove to be complex convolutions of the 
cyst wall. Hence, histologically, Sarcocystis are usually distinguished in 
thin-walled and thick walled species. Small pores allow communication 
between cyst contents and muscle cell content, but apart from the obvious 
nutritional dependence of the parasite on muscle fiber, little is known of 
the biochemical interplay which must take place (Jubb, Kennedy and 
Palmer’s VI edition). 
The most known muscle pathology associated with Sarcocystis spp. 
infection in intermediate hosts, especially cattle, is eosinophilic myositis 
(EM). EM is a subacute to chronic inflammatory myopathy affecting 
skeletal and cardiac muscle, characterized grossly by the presence of 
multifocal greenish to yellowish nodules within affected muscles (Barnes 
et al., 1968, Jensen et al., 1986). These lesions are found at slaughter or 
during meat cutting and result in considerable economic losses. Granstrom 
et al. (1989) speculated that cattle with EM lesions are genetically 
predisposed to produce IgE in response to Sarcocystis bradyzoite antigen, 
and that EM represents an abnormal response to sarcocyst degeneration, 
including a host-dependent, Sarcocystis-specific, type-I hypersensitivity 
(Wouda et al., 2006, Gajadhar et al., 1987). In 2012 Vangeel and 
colleagues were able to sperimentally induce EM intramuscularly injecting 
adjuvanted Sarcocystis antigen in 2 calves (Vangeel et al., 2012). 
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Gabor et al. in 2010 reported a severe necrotizing and histiocytic 
myositis and cellulitis with central caseation associated with multiple 
sarcocysts (S.aucheniae and S. lamacanis) in a Llama. A granulomatous 
myositis associated with Sarcocystis spp. infection has been documented in 
wild ducks and attributed to the initial penetration of muscle fibers or to 
cyst rupture and degeneration (Wobeser et al. 1982). Since the 
inflammatory response was very similar to that in tuberculosis, the authors 
suggested a cell-mediated reaction. Sarcocystis-associated encephalitis and 
myositis characterized by lymphohistiocytic, granulomatous and, 
occasionally, eosinophilic myositis was also described in pigeons and 
associated with a Th1 response (Olias et al., 2009, 2013). Severe chronic 
muscle inflation is very rarely reported in appropriate intermediate hosts 
and clinically relevant cases are sporadic in horses (Traub-Dargatz et al., 
1994). 
Sarcocystis-related muscle pathology is much more severe and 
histologically different in accidental intermediate hosts. Recurrent 
outbreaks of muscular sarcocystosis among tourists visiting islands in 
Malaysia have focused international attention on sarcocystosis (Fayer et 
al., 2015); indeed, humans may become accidental intermediate hosts after 
ingesting sporocysts can develop symptomatic disease including fever, 
myalgia, headache, arthralgia, vomiting and chronic, mainly 
lymphoplasmacytic polymyositis (Greve 1985, Lau et al., 2014, Claire et 
al., Italiano et al., 2012, Esposito et al., 2012, Tappe et al., 2013, Abubakar 
et al., 2013). Less frequently Sarcocystis infection has been associated with 
eosinophilic myositis in humans as well (Arnes et al., 1999). Sporadic 
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reports of aberrant muscular sarcocystosis characterized by severe chronic 
symptomatic myositis has also been reported in dogs (Shasrabudhe et al., 
1966, Blagburn et al., 1989, Sykes et al., 2012, Chapman et al., 2005, 
Sykes et al., 2011), cats (Kirkpatrick et al.,1986) and nonhuman primates 
(Gozalo et al., 2007). 
Taking into account the striking variation in sarcocystis- related muscle 
disease, in addition with the aneddotical observation from our group of 
chronic muscle inflammation in affected ruminants, the aim of this study 
was to investigate if, even in sheep, parasitized muscle fibers could play a 
role in immune-stimulation, as sporadically described in accidental 
muscular sarcocystosis in accidental hosts. 
 
2.2Materials and methods 
2.2.1 Animals: 
 
The study included skeletal muscle biopsies (semimembranosus or 
semitendinosus muscles) from 78 sheep coming from different areas of 
Basilicata Region, that were regulary slaughtered and sampled in the 
contest another large epidemiological study (see Alessandro Costagliola’s 
doctoral thesis, Department of Veterinary Medicine and Animal 
Production, University Federico II of Naples. “New Prospective on 
Sentinel Animal Systems: Experiences in Southern Italy Polluted Areas” 
2017, XXIX cycle). All muscles were immediately transported under 
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refrigeration temperatures at the Laboratory of Comparative 
Neuromuscular disorders of the Department of Veterinary Medicine of 
Naples and snap frozen in isopentane pre-cooled in liquid nitrogen within 2 
hours after sampling. 
2.2.2 Sarcocyst species identification:  
DNA was extracted from 20 frozen muscle samples by using the 
DNeasy Blood and Tissue Kit (QIAGEN, Valencia, CA). Broad spectrum 
Sarcocystis spp. PCR for partial 18S rRNA gene sequence was performed. 
The 18S rDNA gene was amplified by nested polymerase chain reaction 
(PCR) and primer 1L (5′-CCATGCATGTCTAAGTATAAGC-3′) and 
primer 1H (5′-TATCCCCATCACGATGCATAC-3′) in the primary 
reaction, followed by primer 3L (5′-CTAGTGATTGGAATGATGGG-3′) 
and primer 2H (5′-ACCTGTTATTGCCTCAAACTTC-3′) in the 
secondary reaction. Four microliters of DNA template was used in a 25-μL 
PCR sample and the following reaction conditions: 35 mM Tris-HCl, pH 
9.0, 25 mM KCl, 3.5 mM MgCl2, 5 pmoles of each primer, 1 mM dNTPs, 
and 1 unit of polymerase. The PCR was performed as follows: 95°C for 2 
minutes; followed by 35 cycles at 94°C for 40 seconds, 50°C for 30 
seconds, and 72°C for 1.5 minutes; followed by 72°C for 6 minutes. The 
product was separated by agarose gel electrophoresis and Sanger’s 
sequencing performed. Finally BLAST annealing analysis was done to 
identify the species. 
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2.2.3 Histology and immunohistochemistry 
Frozen sections (10 µm thick) were subjected to a standard panel of 
histochemical stains (Paciello, 2009) including hematoxylin and eosin 
(HE), Engel’s trichrome (ET), NADH-tetrazolium reductase (NADH-TR), 
succinate dehydrogenase (SDH), Cytochrome oxidase (COX), ATPase at 
pH 9.4 and 4.3, and periodic acid–Schiff (PAS) reaction. A scoring system 
was designed to assess the degree of fiber atrophy as follows based on 
assessment of 100 fibers at 200X magnification: mild (score 1), <10% 
atrophic fibers; moderate (score 2), 10% to 50% atrophic fibers; and severe 
(score 3), >50% of atrophic fibers. A scoring system was also defined for 
lymphocytic inflammation based on light microscopy: no inflammation 
(score 0); mild inflammation (score 1), 5 to 25 lymphocytes/plasma cells 
per high-power field (HPF) (400X); and moderate inflammation (score 2), 
26 to 50 lymphocytes/ plasma cells per HPF. At least 10 fields at 400X 
magnification were evaluated for each section by 2 independent 
pathologists (T.B.P. and O.P.) under an optical microscope (Nikon E600; 
Nikon, Tokyo, Japan), with a concordance rate of 95%. For 
immunohistochemistry (IHC), frozen sections (8 mm thick) were 
processed with the MACH1 Universal HPRPolymer Detection Kit 
(Biocare Medical LLC, Concord, CA). Briefly, the sections were dried for 
1 hour at room temperature and fixed in acetone at 4C for 3 minutes; 
peroxide block was applied for 15 minutes at room temperature, and then 
the sections were incubated for 30 minutes with background sniper 
(Biocare Medical LLC). The primary antibodies were diluted in phosphate-
Lymphoplasmacytic myositis and expression of MHC I in ovine muscular sarcocystosis 
 
96 
 
buffered saline (PBS) and incubated overnight at 4C. MACH1 mouse 
probe was applied for 20 minutes at room temperature. Horseradish 
peroxidase (HRP)–polymer was added for 30 minutes at room temperature. 
After every step of the procedure, the sections were washed in 0.01 M PBS 
(pH 7.2–7.4). The reaction was revealed by using 3,30- diaminobenzidine 
(DAB) chromogen diluted in DAB substrate buffer. Finally, sections were 
counterstained in Carazzi’s hematoxylin. Primary antibodies were directed 
against major histocompatibility complex I (H58A, mouse monoclonal 
antibody, dilution 1:200; VMRD, Pullman, WA), major histocompatibility 
complex II (H42A, mouse monoclonal antibody, 1:200; VMRD), CD3 
(IS503, rabbit polyclonal antibody, 1:50; Dako, Milan, Italy), CD79a 
(HM57, mouse monoclonal antibody, 1:50; Dako), CD4 (17D1, mouse 
monoclonal, VMRD, 1:50), CD8 (PT36B, mouse monoclonal, VMRD, 1: 
50) and Dystrophin ROD domain (DYS 1, clone Dy4/6D3, Novocastra 
Laboratories Ltd UK, diluition 1: 50). The percentage of muscle fibers with 
sarcolemmal positivity to major histocompatibility complex I and II (MHC 
I and I) was scored as follows: absent/none (score 0), 0%; mild (score 1), 
1% to 25%; and moderate (score 2), 26% to 50%. For evaluation of MHC I 
and II, fibers directly adjacent to the inflammatory infiltrate were avoided, 
since positive endomysial inflammatory cells can make evaluation of 
sarcolemmal positivity difficult. The positive staining for MHC I and II 
varied from a continuous staining throughout the sarcolemma to a 
discontinuous sarcolemmal pattern. Endomysial blood vessels, which are 
normally positive for MHC I and II, were used as positive internal controls 
for immunohistochemistry with anti–MHC I and MHC II antibodies. 
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Frozen section of normal sheep lymph nodes was used as positive controls 
for immunohistochemistry with anti-CD3, CD79a, CD4, and CD8. The 
total inflammation score (IS) was obtained by summing the scores for 
lymphoplasmacytic inflammation, MHC I, and MHC II. 
2.2.4 Immunofluorescence 
To determine if there is a co-localization between Dystrophin and 
Major Histocopatibility Complex I on muscle fibers and on 
parasitophorous vacuole, immunofluorescence was carried out on selected 
cases (n. 10) as follows. Crysections were dried at room temperature for 1 
hour, preincubated with normal mouse serum diluted 1:10, and overlaid 
overnight in a humid chamber at 4°C with primary antibody directed 
against Dystrophic ROD domain (DYS 1, clone Dy4/6D3, Novocastra 
Laboratories Ltd UK, dilution 1: 10). A FITC fluorochrome-labeled rabbit 
anti mouse secondary antibody was applied (1:50; Jackson Laboratories, 
Bar Harbor, ME, USA) on sections for 2 hours at room temperature. Slides 
were rinsed with PBS and a second primary antibody directed against 
MHC I (H58A, mouse monoclonal antibody, dilution 1:10; VMRD, 
Pullman, WA) was applied overnight at 4°C. A TRITC fluorochrome-
labeled rabbit anti mouse secondary antibody was applied (1:50; Jackson 
Laboratories, Bar Harbor, ME, USA) on sections for 2 hours at room 
temperature. Slides were rinsed with PBS and mounted with a solution of 1 
part glycerol/ 1 part PBS. For scanning and photography, a laser scanning 
microscope (LSM 510; Zeiss, Go¨ttingen, Germany) was used with 
illumination at 488 nm and read using a 505- to 560- nm band pass filter. 
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As a negative control, serial sections of muscle were incubated with PBS 
omitting the primary antibody. 
2.2.5 Statistical analysis.  
For measuring the association between  
1) number of cysts and: inflammation, number of cysts and MHC I 
and II score, and inflammation score (IS) 
2) atrophy score and: inflammation, number of cysts and MHC I and 
II score, and inflammation score (IS) 
3) inflammation, MHC I, MHC II, inflammation score and number of 
MHC I and DYS1 positive cysts. 
Statistical analysis was performed using SSPS software with a level of 
significance of 0.005. The correlations were performed using the Pearlson 
correlation test. 
2.3 Results: 
2.3.1 Sarcocystis species identification: 
 All samples tested revealed 100% identity to Sarcocystis tenella by 
BLAST alignment (Fig 2.1). 
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Fig. 2.3: Sarcocystis species identification. A distinct 500bp band at PCR was found (consisiting with 
Sarcocystis 18S rRNA gene sequence). Then, sequence alignment by BLAST database revealed 100% of identity 
to S. tenella. 
2.3.2 Histology and Immunohistochemistry 
 
Detailed results of histopathology and immunohistochemistry are 
presented in Table 2.2. 
 
case 
number 
cysts 
number atrophy inflammation MHC I MHC II CD4 CD8 CD79 
MHC I 
positive 
Cysts 
Dys 1 
positive 
cysts 
infl. score 
(inflammation+MHC 
I+MHC II) 
1 9 1 0 2 2 0 0 0 0 0 4 
2 7 2 0 1 1 0 0 0 0 0 2 
3 3 1 0 0 0 0 0 0 0 0 0 
4 11 0 0 2 1 0 0 0 0 0 3 
5 15 1 0 2 2 0 0 0 5 0 4 
6 9 0 0 1 1 0 0 0 0 0 2 
7 10 1 0 1 1 0 0 0 4 0 2 
8 1 1 0 2 2 0 0 0 0 0 4 
9 13 1 0 3 2 0 0 0 0 0 5 
10 0 1 0 0 0 0 0 0 0 0 0 
11 4 0 0 1 1 0 0 0 0 0 2 
12 10 1 0 1 1 0 0 0 5 0 2 
13 7 1 0 1 1 0 0 0 0 0 2 
14 60 2 0 2 1 0 0 0 1 1 3 
15 17 0 0 2 2 0 0 0 2 2 4 
16 2 2 0 1 1 0 0 0 0 0 2 
17 8 0 0 1 1 0 0 0 3 0 2 
18 3 0 0 1 1 0 0 0 1 0 2 
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case 
number 
cysts 
number atrophy inflammation MHC I MHC II CD4 CD8 CD79 
MHC I 
positive 
Cysts 
Dys 1 
positive 
cysts 
infl. score 
(inflammation+MHC 
I+MHC II) 
19 5 1 0 2 2 0 0 0 2 0 4 
20 32 2 0 2 2 0 0 0 12 1 4 
21 3 1 0 1 1 0 0 0 2 0 2 
22 8 2 0 1 1 0 0 0 3 0 2 
23 6 0 0 1 1 0 0 0 3 0 2 
24 20 1 1 3 1 1 2 0 13 2 5 
25 23 1 1 2 3 1 2 1 10 2 6 
26 4 2 1 2 2 0 2 0 0 0 5 
27 16 1 1 2 1 1 2 1 5 0 4 
28 9 1 1 2 1 1 2 0 5 0 4 
29 4 1 1 1 1 1 1 1 2 0 3 
30 10 1 1 3 3 1 3 0 4 0 7 
31 18 2 1 3 3 2 2 1 12 3 7 
32 8 1 1 2 2 1 2 0 3 0 5 
33 10 1 1 2 2 0 1 0 4 0 5 
34 13 1 1 2 2 1 2 0 4 0 5 
35 7 1 1 2 2 1 1 0 4 0 5 
36 8 0 1 2 2 1 1 0 5 0 5 
37 26 1 1 2 3 1 2 0 11 0 6 
38 23 2 1 1 1 0 1 0 14 0 3 
39 2 1 1 1 1 0 1 1 0 0 3 
40 19 2 1 2 2 0 1 0 15 2 5 
41 26 2 1 1 0 0 1 0 2 0 2 
42 4 2 1 1 1 1 0 1 1 0 3 
43 8 2 1 1 1 1 2 1 12 0 3 
44 28 2 1 3 3 1 2 0 15 0 7 
45 4 2 1 2 2 1 2 0 0 0 5 
46 15 2 1 2 2 1 3 0 4 0 5 
47 21 2 1 1 1 0 1 0 10 0 3 
48 2 1 1 2 2 1 1 0 0 0 5 
49 2 0 1 1 1 0 2 1 0 0 3 
50 7 1 1 1 1 1 2 1 0 0 3 
51 1 1 1 2 3 2 2 0 0 0 6 
52 4 1 1 2 2 1 3 0 0 0 5 
53 17 1 1 3 3 1 1 0 10 4 7 
54 10 1 1 3 2 2 3 0 4 0 6 
55 2 2 1 2 1 1 2 0 0 0 4 
56 10 1 2 3 2 2 3 0 3 0 7 
57 0 0 2 1 1 2 3 0 0 0 4 
58 4 2 2 1 1 2 2 0 0 1 4 
59 1 1 2 3 3 + 2 0 0 0 8 
60 22 1 2 3 2 1 2 1 9 3 7 
61 20 1 2 1 1 1 2 0 8 3 4 
62 9 1 2 2 1 2 3 0 8 0 5 
63 35 1 2 1 2 1 2 0 13 3 5 
64 22 0 2 1 + 2 3 0 15 2 3 
65 2 2 2 2 1 1 3 1 2 0 5 
66 7 2 2 2 1 2 3 0 2 0 5 
67 70 1 2 3 2 1 3 0 30 10 7 
68 6 3 2 3 2 1 2 0 3 0 7 
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case 
number 
cysts 
number atrophy inflammation MHC I MHC II CD4 CD8 CD79 
MHC I 
positive 
Cysts 
Dys 1 
positive 
cysts 
infl. score 
(inflammation+MHC 
I+MHC II) 
69 25 3 2 3 2 2 2 1 12 0 7 
70 11 0 2 2 2 0 1 0 4 0 6 
71 9 2 2 2 1 1 2 0 7 4 5 
72 30 1 2 2 1 1 2 0 13 4 5 
73 8 1 2 3 3 1 3 1 7 0 8 
74 15 1 2 3 1 0 2 1 10 0 6 
75 9 2 2 1 1 1 2 0 6 0 4 
76 18 2 3 3 3 2 3 1 17 1 9 
77 58 1 3 3 3 1 3 0 32 11 9 
78 6 1 3 2 1 2 2 0 6 0 6 
Table 2.2 Summary of histopathological findings. 
 
As expected, intra-sarcoplasmic round to oval, septate sarcocysts 
(ranging from 3 to 60 cysts/cm
2
) with thin wall (<1 µm), containing 
myriads of cresent-shaped bradyzoites (Fig. 2.4, A) were detected in the 
vast majority of muscle biopsies (97,2 % -76 out of 78) of cases.  
72% (55 out 76) of cases showed inflammatory changes scored as 
mild (58,1% - 32 out of 55), moderate (72% -30 out of 55) or severe (5,4% 
- 3 out of 55). Inflammation consisted of multifocal endomysial foci of 
lymphoplasmacytic inflammation (Fig. 4, C), occasionally centered around 
parasitized cysts (Fig. 2.4, B) or arranged in perivascular cuffs. 
Multifocally, in about 30% of cases. lymphocytes and plasmacells were 
admixed with esterase positive macrophages (Fig. 2.4, D) or invaded 
necrotic muscle fibers (sarcoclastosis). Notably, eosinophils were 
constantly absent. 
Increased variability in fiber size was a prominent finding in almost 
all cases (85,8% -67 out of 78) and was classified as mild in 61% of cases 
(41 out of 67), moderate in 34% of cases (23 out of 67) and severe in 2,9% 
of cases (2 out of 67).  
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In more inflamed cases (30%) mitochondrial abnormalities such as 
central palor and presence of “moth eaten” fibers were observed at 
histoenzimatic stains COX (Fig. 2.4 E), NADH and SDH. 
Sarcolemmal overexpression of MHC I (Fig. 2.3 A) was detected in 
76 out of 78 cases (97,4%), that is both in biopsies with evident 
inflammatory infiltrate and in cases without visible inflammation. It was 
score as mild in 26 cases out of 76 (34%), moderate in 32 cases (42,7%) 
and severe in 17 cases (24,3%). Similarly, MHC II (Fig. 2.3 B) was 
positive in 96% of cases (3 animals) and classified as mild in 36 cases 
(48%), moderate in 26 cases (34,6%) and severe in 11 cases (14,6%). 
The predominant lymphocytic populations were CD3+, CD8+ with 
lesser numbers of CD4+ (Fig. 2.5). CD79+ cells were present in 15/55 
(27%) of cases showing inflammatory infiltrate at hematoxylin and eosin 
stain. T lymphocytes were predominantly CD8+ in 63% of cases (35/55) 
and purely CD8 + in 18% of cases (10/55) (Fig. 2.5). In 8 cases (14%) 
CD4+ and CD8+ lymphocytes were in an equal proportion. Only in 1 case 
CD4 positive lymphocytes were more represented than CD8 positive 
lymphocytes. 
In 56 cases (73%) MHC I labeled also the wall of the cysts in a 
scattered, inconstant fashion (Fig. 2.6 A, C, F); three different staining 
pattern of MHC I immunopositivity were observed: in most cases only the 
cysts wall was immunopositive (Fig. 2.6 C- about 70%). Parasitized 
muscle fibers displayed occasional immunopositivity to MHC I without 
positivity on the sarcolemma (Fig. 2.6 D- about 5%). In few cases (about 
5%), and especially when accompanied by prominent inflammatory 
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infiltrate, both the sarcolemma and the cyst wall resulted MHC I positive 
(Fig. 2.6 E). In remaining 20% of parasitized muscle fibers both the 
sarcolemma and the cyst wall were negative to MHC I. 
2.3.3 Immunofluorescence 
To explore a possible co-localization between the sarcolemmal 
protein Dystrophin and Major histocompatibility complex I, 
immunofluorescence was performed on cases displaying Dystrophin 
positivity on the cyst wall at immunohistochemistry (n. 19 cases-20%).  
The cyst wall immunopositivity to Dystrophin was confirmed only 
in 9 cases and in a small percentages of cases (less than 10% of the cysts in 
the section), but, when positive a granular, multifocal co-localization 
between MHC I and Dys I was observed (Fig. 2.7 E-F). No positivity was 
detected in sections incubated with PBS rather than primary antibodies. 
2.3.4 Statistical analysis 
 The number of cysts was positively correlated with inflammation 
degree (P< 0,05 =0,04) , inflammation score (P< 0,05 =0,04) , MHC I and 
MHC II score (P< 0,05 =0,004) and number of MHC I positive cyst wall 
(P< 0,05 =0,00001).  
The atrophy score was not correlated with inflammation degree (P=0,07) 
and inflammation score (P=0,09).  
MHC I, MHC II and inflammation score were positively correlated with 
the number of MHC I and DYS1 positive cysts (P=0,001, 0,0001, 
respectively). 
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Fig. 2.4 Histopathology. Hematoxylin and eosin (A-C), nonspecific esterase (D) and COX stain (E). A) Thin 
walled, septate sarcocyst containing myriad of banana shaped bradizoytes. B) lymphocytic infiltrate surrounding 
a parasitized muscle fiber. C) endomysial chronic infiltrate. E) esterase positive inflammatory infiltrate 
consisting with macrophages. F) fibers with abnormal COX staining: “moth eaten” aspect and central pallor. 
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Fig. 2.5: immunohistochemistry. HRP method, hematoxylin counterstain. A and B: MHC I and II were 
overexpressed on the sarcolemma of muscle fibers. Inflammatory cells associated with parasitized cysts (C) or 
arranges perivascularly (D) are MHC I and II positive, respectively. The inflammatory infiltrate is 
predominantly CD8 positive (E, F). CD8 positive lymphocytes invade a parasitized (G) or not parasitized (H) 
fiber. 
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Fig. 2.6 Immunohistochemistry and Immunofluorescence. (A) MHC I labels the wall of the cysts in a scattered 
fashion, with sparse negative cysts (arrow). (B) In a small percentage of cases DYS 1 labeled the wall of the 
cysts (arrow). (C-E) Three different combination s of staining pattern of MHC I: cyst wall positive, sarcolemma 
negative (A), sarcolemma positive, cyst wall negative (B), both sarcolemma and cyst wall positive (D). (E) The 
MHC I labeled the cyst wall and the sarcolemma also in immunofluorescence. (F). Dapi nuclear stain shows 
myriads of bradyzoite nuclei within the cyst. 
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Fig. 2.7: Immunofluorescence. MHC I (red, TRIC) labeling of parasitophorous vacuole and cyst septa (A) or 
membrane of parasitized fiver with partial labeling of the internal portion of the cyst (B). Anti-Dystrophin 
antibody (DYS 1, green FITC ) distinctly labels the sarcolemma (C, D) and partially the cysts (C,D). MHC I and 
DYS 1colocalize on the sarcolemma of a parasitized fiber (F) and focally the internal portion of the cyst (E,F 
merge, orange color). 
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2.4 Discussion 
As shown in the introduction, despite Sarcocystis is widely 
regarded as a “silent” muscle pathogen, it is associated with a wide range 
of disease manifestation, ranging from localized forms (eosinophilic 
myositis), to acute and peracute systemic febrile disease and abortion 
during endothelial schizogony phase (Dalmey disease) as well as clinically 
relevant polymyositis in accidental intermediate hosts. These different 
clinical manifestations are partly imputable to different phases of the 
lifecycle of the parasite and partly to the degree of adaptation of the host’s 
immunitary system.  
 Lymphoplasmacytic infiltrate associated with muscular 
sarcocystosis in appropriate intermediate host is occasionally mentioned in 
the literature (Jeffrey et al., 1989, Buxton et al., 1989, Jubb Kennedy and 
Palmers 2017); however, an accurate incidence analysis and 
histopathological characterization of this inflammatory change has not 
been documented so far.  
We reported a variable degree of chronic lymphoplasmacytic 
infiltrate in 72% of muscle biopsies of sheep naturally infected with 
Sarcocystis tenella, and the percentage of inflammation positive cases 
becomes even higher considering the sarcoplasmic expression of MHC I 
and II (97%) as a more sensitive indicator of muscle inflammation.  
Statistical analysis revealed that the degree of muscle inflammation, 
either in terms of inflammatory infiltrate either of MHC I sarcolemmal 
expression, is positively correlated with the number of cysts, confirming a 
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strong relationship between the etiological agent and histological markers 
of inflammation. 
However, since the distribution of cysts is not always homogeneous 
within a muscle group, when parasites are not visible in histopathological 
sections, the presence of Sarcocystis can not be immediately ruled out in 
case of muscle inflammation. 
Complexively, our results indicate that chronic inflammation in 
ovine muscular sarcocystosis is likely underestimated. The presence of 
inflammatory infiltrate, mainly consisting of CD3/CD8 positive T 
lymphocytes, together with the strong sarcolemmal immunopositivity to 
MHC I suggest that parasitized muscle fibers are not merely inert “victims” 
of intracellular parasitism, but, as in other myopathies, may play an active 
role in antigen presentation and in maintaining pathological events 
(Englund, 2001; Paciello, 2007, Paciello 2009). If so, this common 
protozoal disease should be included in the differential diagnosis of 
polymyositis in many species of animals, including humans; furthermore it 
should be excluded before considering idiopathic and immune-mediated 
myopathy as underlying condition of muscle inflammation.  
Expression of MHC class I and II antigens on the surface of muscle fibers 
has already been described in other infectious (i.e. Toxoplasma and 
Leishmania related myositis- Matsubar. 1990, Paciello, 2009) and 
immune-mediated myositis of humans and dogs (Dalakas, 2011, Vattemi, 
2014). Indeed, increasing evidences suggest that myositis formerly 
considered “idiopathic” are in fact related to underlying systemic parasitic 
and viral diseases triggering immune-mediate muscle damage in both 
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humans and dogs (Paciello, 2009, Evans, 2004, Dalakas, 2010). For those 
reasons it is possible that in a close future these two entities (infective and 
immune-mediated myositis) would be considered partially overlapping. 
Differently from the previous chapter, in which we described a 
presumptive immune-mediated myositis in horses affected by chronic 
piroplasmosis, in sarcosystis-related myositis the etiological agent is 
clearly detectable within muscle tissue; this means that the parasite can 
induce muscle damage and trigger muscle inflammation in at least two 
different ways: I) by a direct damage to the cell or, less likely, II) 
stimulating an immune-mediated by a possible molecular mimicry between 
self and parasite’s antigens (see chapter 1). 
The direct role of Sarcocystis in inducing a cell damage possibly 
stimulating the MHC I overexpression may be related to the perturbance of 
endoplasmic reticulum (ER) homeostasis (ER stress). ER stress 
(Rayavarapu, 2012) is reported in response to intracellular parasitism 
(Galluzzi et al. 2017) and in human inflammatory myopathies (Vattemi, 
2004, Nagaraju 2005). In mammalian cells ER stress activates the unfolded 
protein response (UPR), that is an elaborate signaling cascade activated to 
restore ER homeostasis and ensure cell survival mediated by three 
transmembrane proteins: IRE1, that stimulates the production of 
proinflammatory cytokines and stimulates autophagy, PERK, that activates 
an antioxidant response, and ATG6, that is involved in the regulation of 
protein folding and lipid synthesis.  
In our samples, prominent mitochondrial abnormalities were detected in 
more severely inflamed cases (30%). Mitochondrial abnormalities are 
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frequently associated with muscle inflammation, as reported in several 
human inflammatory myopathies where they are generally associated with 
damage to the mitochondrial DNA (Oldfors, 2006; Varadhachari, 2010). 
Mitochondrial damage can activate ER stress since the endoplasmic 
reticulum has an intimate contact with mitochondria in specialized areas 
called mitochondria-associated ER membranes (MAM). It is thus 
conceivable that ER stress pathways and mitochondria work together to 
cause myofiber damage also in Sarcocystis related myositis. ER stress 
itself has been associated with the activation of inflammatory responses in 
skeletal muscle: NF-κB, JNK, interleukin-6, and TNF-α have been shown 
to be activated by ER stress mechanisms (Nagaraju, 2005). 
A novel and interesting finding of our work, is the expression of 
MHC I and II on the parasitophorous vacuole of Sarcocystis. To the 
author’s knowledge, the same finding was described only once in the 
literature, in a severe case of myositis in a dog being an accidental 
intermediate host of Sarcocystis spp (Sykes, 2011), and interpreted as an 
active involvement of this parasite’s structure in the pathogenesis of 
muscle inflammation.  
In apicomplexan parasites, the parasitophorous vacuole membrane (PVM) 
derives from the host cell plasmalemma, whose biochemical composition 
undergoes significant changes as the intravacuolar parasite grows. In 
particular, the host cell proteins are progressively and selectively excluded 
from the parasitophorous vacuole membrane, while those of the parasite 
are incorporated. As the result, the changed PVM becomes not fusigenic 
for host cell lysosomes (Beier, 2003) and is protected from the immunitary 
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system of the host. In our study, in approximately 20% of cases, scattered 
cysts expressed the sarcolemmal protein Dystrophin and co-localized with 
MHC I in 10% of cases. This finding could be explained with an 
incomplete exclusion of host cell protein from the parasitophorous cell 
membrane; how this finding could influence the inflammatory machinery 
is unknown.  
The immunostaining pattern to MHC I on parasitized fibers displayed at 
least four three different combinations: cyst-only immunopositivity (70%) 
sarcolemma-only positivity (5%), both sarcolemma and cyst wall positivity 
(5%), no staining of both structures (20%). The percentage of MHC I 
positive parasitized fibers was statistically correlated to the overall MHC I 
positivity score, to the inflammation score and to the number of cysts 
present into the sections. If the positivity of the cyst wall appears before or 
after the sarcolemmal one is not known but can be an interesting issue for 
further research about the pathogenesis of muscular sarcosystosis. 
The reasons underlying the different combination staining patterns 
are unknown but may reflect different stages of immunitary activation of 
the parasitized muscle fibers or be the consequence of cysts’ degeneration, 
that is considered the most relevant factor triggering inflammation in 
muscular sarcocystosis. Further research is needed to explore this 
hypothesis. 
In conclusion, we systematically described and characterized an 
inflammatory myopathy concomitant with muscle sarcosystosis in sheep. 
This condition is characterized by infiltration of mainly CD8+ T 
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lymphocytes and expression of MHC I and II on the fiber surface and, by a 
still poorly understood mechanism, on the parasitic cyst wall.  
Our data suggest also that the sheep may represent a good animal model 
for the study of immunopathogenesis of chronic muscle inflammation in 
muscular sarcocystosis possibly associated with clinical syndromes in 
humans. 
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3.1 Introduction 
Sarcopenia, the age related loss of muscle mass and strength, is a 
multifactorial condition that occurs in a variety of species and represents 
A major healthcare concern for older adults in human medicine (Evans, 
1995; Doherty, 2003; Buford et al., 2010). A decline in muscle mass 
generally indicates a degradation in muscle protein content and several 
studies have demonstrated an age-related reduction in the synthesis of 
specific muscle proteins (Proctor et al., 1998; Nair, 2005; Augustin and 
Partridge, 2009) with a concurrent increase in proteolysis. Skeletal muscle 
has four main proteolytic systems, namely, lysosomal, caspase, calpain and 
ubiquitin– proteasome, all of which could potentially contribute to age 
related muscular atrophy. 
Autophagy is a ubiquitous and highly conserved catabolic process, which 
involves intracellular degradation of cytoplasmic components through a 
lysosomal pathway. The process is involved in a variety of mechanisms 
related to ageing, including mitochondrial turnover, removal of misfolded 
protein aggregates and apoptosis. It has been proposed that age-related 
alterations in autophagy might play a major role in sarcopenia (Tukaj, 
2013). 
Three main types of autophagy have been described: (1) microautophagy, 
in which lysosomes directly take up portions of cytoplasm for degradation; 
(2) chaperone-mediated autophagy, in which chaperone proteins recognize 
and transport cytoplasmic proteins to the lysosome; and (3) 
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macroautophagy, where there is non selective sequestration of cytoplasmic 
material for lysosomal degradation. The latter process has been the focus 
of a large body of research and represents the most important type of 
autophagy (Tukaj, 2013; Wojcik, 2013); it consists of several steps, 
specifically induction or initiation and cargo selection, vesicle nucleation 
and expansion, lysosomal targeting, lysosome docking and 
autophagosome–lysosome fusion, vesicle breakdown and recycling 
(Klionsky and Emr, 2000; Tooze and Schiavo, 2008). Nucleation is 
considered to be a crucial event that generates an active phagophore (or 
isolation membrane), which is the foundation kinases required for 
autophagy (Ulk1/2) function together with the Class III 
phosphatidylinositol 3-kinase (PI3K) VPS34 complex, which contains 
Beclin 1 (Tukaj, 2013). For phagophore expansion, elongation and 
sequestration into double-membrane vesicles (autophagosomes), 
recruitment of microtubule-associated protein light chain 3 (LC3)-II is 
required (Longatti and Tooze, 2009). 
Sequestration of ubiquitinated cargo within the phagophore is greatly aided 
by p62/SQSTM-1 (Pankiv et al., 2007). The nascent autophagosomes 
subsequently fuse with lysosomes to form an autophagolysosome, in which 
the cytoplasmic cargo is degraded by lysosomal acid hydrolases and where 
the degradation products are recycled (Tukaj, 2013). 
The aims of the present study were to investigate whether autophagy was 
up-regulated in skeletal muscle from older dogs affected by sarcopenia, 
compared with similar tissues from younger healthy dogs, and to determine 
whether the size of the dog influenced this process. 
Age related skeletal muscle atrophy and upregulation of autophagy in dogs 
 
123 
 
3.2: Materials and methods 
3.2.1 Animals and tissue samples 
Twenty-five dogs (10 male, 15 female) of various breeds, aged 
between 15 and 22 years of age, were recruited into the study (Table 3.1). 
The dogs had died of natural causes or had been euthanized with informed 
owner consent by means of intravenous injection of 10 mg/kg Pentothal 
(Abbott Laboratories) and 70 mg/kg Tanax (MSD Animal Health). None 
of the study dogs showed any clinical evidence of neuromuscular disease 
or metabolic diseases including hypothyroidism, hyperadrenocorticism, 
renal disease, diabetes mellitus or neoplasia. None of the study dogs had a 
history of inappetence prior to entry into the study or had recently received 
glucocorticoid therapy, or any other drugs known to have an effect on 
muscle tissue. Each owner consented to necropsy and use of tissues for 
research purposes, according to the ethical guidelines of the Diagnostic 
Service of the Department of Pathology and Animal Health of the 
University of Naples Federico II. Immediately post-mortem, muscle 
biopsies of approximately 1–2 cm diameter were obtained from the biceps 
femoris muscle. All samples were frozen in isopentane pre-cooled in liquid 
nitrogen, and stored at −80 °C until further processed. Biopsies of biceps 
femoris muscle, obtained from five healthy young dogs, aged between 2 
and 5 years (Table 3.1), euthanized for reasons unrelated to the study, were 
used as control tissue for histological, immunohistochemical and Western 
blotting analyses, again with owner consent. 
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Case 
# 
Breed Sex Weight Age 
(years) 
Muscle atrophy 
1 Rottweiler F > 10 kg 15 yes 
2 Mix breed M < 10 kg 17 yes 
3 Pitt Bull F < 10 kg 16 yes 
4 Mix breed M < 10 kg 16 yes 
5 Spitz FS < 10 kg 18 yes 
6 Mix breed FS < 10 kg 16 yes 
7 German shepherd M > 10 kg 15 yes 
8 Labrador M > 10 kg 19 yes 
9 Mix breed M > 10 kg 16 yes 
10 Poodle FS < 10 kg 18 yes 
11 Mix breed M > 10 kg 16 yes 
12 Mix breed F < 10 kg 18 yes 
13 German shepherd F > 10 kg 16 yes 
14 Mix breed F < 10 kg 19 yes 
15 Mix breed FS < 10 kg 21 yes 
16 German shepherd FS > 10 kg 17 yes 
17 Boxer M > 10 kg 16 yes 
18 Yorkshire FS < 10 kg 17 yes 
19 Yorkshire F < 10 kg 18 yes 
20 Setter F > 10 kg 17         yes 
21 Mix breed M  <10 kg 19 yes 
22 Mix breed FS >10 kg 18 yes 
23 Doberman M > 10 kg 15 yes 
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24 Labrador M > 10 kg 16         yes 
Case 
# 
Breed Sex Weight Age 
(years) 
Muscle atrophy 
25 Yorkshire F < 10 kg 20 yes 
26 Mix breed M <10 kg 3 no 
27 German shepherd F >10 kg 5 no 
28 Mix breed FS <10 kg 4 no 
29 Labrador M >10 kg 2 no 
30 Yorkshire M <10 kg 3 no 
Table 3.1 Study population. M, male; F, female; FN, female neutered. 
3.2.2 Histological examination 
Tissue sections of 10 μm were cut in a transverse plane with a 
cryostat (−20 °C) and were stained according to the methods detailed 
previously (Paciello and Papparella, 2009). Briefly, haematoxylin and 
eosin (H&E) and Engel trichrome were used for a basic morphological 
examination of muscle fibers; NADH-tetrazolium reductase (NADH-TR), 
succinic dehydrogenase (SDH) and cytochrome oxidase (CYOX) were 
used to indicate activity and distribution of mitochondria; ATPase at pH 
9.4 and pH 4.3 was employed for histochemical fiber subtyping; and 
esterase staining was used to evaluate lipofuscine aggregates inside muscle 
fibers. 
Scoring of the major morphological alterations, observed in the biopsies, 
was performed by light microscopy at 20× magnification. The proportions 
of atrophic fibers, necrotic fibers, ragged and pre-ragged red fibers, 
rimmed vacuoles, CYOX negative fibers and accumulation of lipofuscines 
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were scored as follows: 0 (none); 1–25% of affected fibers (classified as 
mild); 26–50% of affected fibers (classified as moderate); >50% of 
affected fibers (classified as severe). Approximately 20 fields at 20× 
magnification were evaluated for each section by two independent 
pathologists (TBP, OP) with a concordance rate of 95%.  
3.2.3 Immunohistochemical examination  
Immunohistochemical analysis was performed according to the 
method previously described (Paciello and Papparella, 2009). Briefly, 10 
μm sections of muscle tissue were obtained using a cryostat. Slides were 
air dried for 1 h at room temperature, washed in phosphate-buffered saline 
(0.01 M PBS, pH 7.2) and fixed in acetone at 4 °C for 3 min. Endogenous 
peroxide activity was blocked using 0.3% hydrogen peroxide in methanol 
(Sigma–Aldrich), applied for 15 min at room temperature. 
After two washes in PBS, sections were incubated for 30 min at room 
temperature with Background Sniper (BiocareMedical). Sections were 
incubated overnight at 4 °C with the primary antibodies against Beclin-1 
(Santa Cruz Biotechnology) diluted 1:300; LC3 (Abcam), diluted 1:3000; 
and p62 (Santa Cruz Biotechnology), diluted 1:200 in PBS. The 
immunoblot confirmed the specificity of these antibodies in canine tissues 
in accordance with guidelines published by Kurien et al. (2011). After two 
washes with PBS, the MACH 1 Universal HPR-Polymer Detection Kit 
(Biocare Medical) was used according to the manufacturer’s instructions. 
The sections were subsequently counterstained in haematoxylin, 
dehydrated in alcohol, clarified in xylene and mounted in aqueous 
Age related skeletal muscle atrophy and upregulation of autophagy in dogs 
 
127 
 
mounting medium. In the corresponding negative control sections, the 
primary antibody was either omitted or replaced with a 1:20 dilution of 
mouse serum (for p62 antibody) or rabbit serum (for Beclin-1 and LC3) 
(Jackson ImmunoResearch). The degree of immunoreactivity was 
categorized as follows: 0, negative staining observed in muscle fibers; 1–
25% positively stained fibers; 26–50% positively stained fibers; > 50% 
positively stained fibers. 
3.2.4 Western blotting 
Muscle tissues from geriatric dogs and young control dogs were 
sectioned at 20 μm by cryostat and lysed at 4 °C in 200 μL of lysis buffer 
(TBS, 20 mM Tris-HCl pH 7.6, 140 mM NaCl, 30 mM sodium 
pyrophosphate, 5 mM EDTA, 0.55% Nonident P40, 1% Triton X-100, 
50mM NaF, 0.1mM Na3VO4, 1mM PMSF, 1mM benzamidine, 1 mM 
iodoacetamide, 1 mM phenantroline). Protein concentrations were 
determined by BCA protein assay (Pierce), and lysates were adjusted to 
equivalent concentrations with lysis buffer. Aliquots of muscle lysate (30 
μg protein per lane) were then separated by SDS-PAGE. Proteins were 
transferred to PVDF membranes 
and blocked overnight at 4 °C with 5% non-fat dried skimmed milk 
(Marvel, Premier Beverages) in Tris-buffered saline, supplemented with 
0.05% Tween 20 (TTBS). Membranes were incubated with primary 
antibodies against Beclin-1 (Santa Cruz Biotechnology) at 1:500 dilution, 
LC3 (Abcam) at 1:3000 dilution or p62 (Santa Cruz Biotechnology) at 
1:500 dilution. Horseradish peroxidase-conjugated secondary antibodies 
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were applied in blocking solution for 1 h at room temperature. 
Immunoreactive bands were visualized by autoradiography using Super 
Signal West Pico Chemiluminescent Substrate Kit (Pierce). Membranes 
were subsequently stripped and re-probed using anti-β-actin monoclonal 
antibody (Sigma-Aldrich) to confirm equal loading of proteins in all lanes. 
Band intensities were determined on scanned images using Image J 
software1 to determine average pixel intensity. 
3.2.5 Statistical methods 
Data obtained from Western blotting were analyzed with Stat view 
software (Abacus Concepts) by one-factor analysis of variance (single-
factor ANOVA). Data comparing aged vs. young dogs from assessment of 
immunohistochemistry and morphology, including comparisons of Beclin-
1 and LC3 immunoreactive fiber distribution 
in the groups of dogs lighter than 10 kg and heavier than 10 kg, were 
compared using Fisher’s exact test. Differences in the gender distribution 
were assessed using Chi-squared tests of homogeneity and independence. P 
values <0.05 were considered statistically significant. 
3.3 Results 
3.3.1 Histochemical analysis 
In the muscle biopsies from the geriatric dogs, fiber atrophy was observed 
significantly more frequently compared with the control biopsies (P < 
0.001; Table 3.2). H&E staining of muscle tissues from the geriatric dogs 
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showed variability in the fiber diameter sizes and mild, moderate or severe 
fiber atrophy (Fig. 3.1a). Staining for ATPase performed at pH 4.3 and 9.4 
showed that atrophy involved mainly type II fibers (Fig. 3.1b). In the 
majority of the older animals, the number of atrophic fibers varied from 
1% to 25%, but more pronounced atrophy (>25% of fibers) was observed 
in several of the older dogs (Table 3. 2). 
The frequency of necrotic fibers within muscle biopsies was significantly 
greater (P < 0.05) in the geriatric dogs compared with similar samples from 
the young dogs. In most cases, fiber necrosis was categorized as mild 
(Table 3.2) and sometimes sarcoclastosis was also observed. Rimmed 
vacuoles were observed within some muscle fibers (Fig. 3.1c) that were 
classified as mild in most cases, although these were moderate in other 
dogs (Table 3.2). However, the prevalence of rimmed vacuoles was not 
significantly different comparing geriatric and young dogs (P = 0.1). 
A few angulated atrophic fibers and rare pyknotic nuclear clumps were 
also observed. Engel trichrome staining revealed the presence of pre-
ragged and ragged red fibers (Fig. 3.1d) indicating mitochondrial 
proliferation. This phenomenon was more prevalent in the muscle biopsies 
from the geriatric dogs (graded mild to moderate; Table 3.2) compared 
with those from the young dogs (P < 0.05). 
In the muscle biopsies from the geriatric dogs, alterations in CYOX 
activity were observed. Moth-eaten fibers, sub-sarcolemmal mitochondrial 
collection and partially or totally negative fibers were observed (Fig. 3.1e), 
indicating mitochondrial dysfunction. The prevalence of biopsies with 
CYOX negative fibers was significantly greater in the muscle biopsies 
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from the geriatric dogs (graded mild to moderate; Table 3.2) compared 
with those from the young dogs (P < 0.05). Esterase staining revealed 
intracytoplasmic material, consistent with accumulation of lipofuscines 
(Fig. 3.1f). This accumulation of lipofuscine within muscle fibers was 
significantly more prevalent in the muscle biopsies from the geriatric dogs 
compared with those from the young dogs (P < 0.05; Table 3.2). NADH-
TR and SDH stains showed dysfunctional mitochondria distribution, 
associated with the presence of moth-eaten fibers (data not shown). There 
Were no significant differences in any of the histochemical parameters 
comparing muscle biopsies from male and female dogs within the geriatric 
dog group or between bodyweight categories. 
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Fig. 3.1: Representative histological sections of biceps femoris muscle from geriatric dogs. (a) H&E staining 
showing atrophic muscle fibres (arrow). Bar = 40 μm. (b) ATPase staining showing that atrophy involves mainly 
type II fibres (arrow). Bar = 35 μm. (c) Engel trichrome staining showing fibers with subsarcolemmatic rimmed-
vacuoles (arrow). Bar = 30 μm. (d) Engel trichrome staining showing muscle fibers with mitochondrial 
proliferation in subsarcolemmatic zone (arrows). Bar = 30 μm. (e) CYOX staining showing several moth-eaten 
fibers, and a CYOX negative fiber (arrow). Bar = 50 μm. (f) Non-specific esterase staining showing 
intracytoplasmic material, compatible with accumulation of lipofuscines (arrows). Bar = 50 μm. 
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3.3.2 Immunohistochemistry 
Muscle biopsies from the healthy dogs were negative on 
immunohistochemistry for Beclin-1, LC3 and p62 (data not shown). In 
muscle biopsies from the geriatric dogs, Beclin-1 and LC3 
immunoreactivity was observed in 21/25 samples (Table 3.2). 
Interestingly, the majority of tissue samples demonstrating >25% Beclin-1 
positive fibers also contained fibers with rimmed vacuoles. Beclin-1 
expression was observed as spots within individual muscle fibers, or as 
whole fibers with moderate to strong intensity of immunoreactivity (Fig. 
3.2a). Some muscle biopsies showed subsarcolemmal Beclin-1 
immunoreactivity in almost 10% of fibers. LC3 immunoreactivity (Fig. 
3.3a) was more variable in terms of the proportion of positive fibers (Table 
3.2). 
In contrast to Beclin-1 and LC3, p62 immunoreactivity was observed in 
only 3/25 muscle biopsies, with few fibers showing small spots of 
immunoreactivity (Fig. 4a). In the p62 positive cases, biopsies 
demonstrated LC3 immunoreactivity in >25% of muscle fibers (Table 3.2). 
3.3.3 Western blotting analysis 
Expression of Beclin-1, LC3 and p62 was investigated in muscle tissue 
lysates by Western blotting. Immunoreactivity for Beclin-1 (60 kDa band; 
Fig. 3.2b) and for the two isoforms of LC3 (18 kDa band for LC3 I and 16 
kDa band for LC3 II; Fig. 3.3b) and p62 (62 kDa band; Fig. 3.4b) was 
identified. Densitometry results, normalised for β-actin expression, showed 
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a significant difference in expression of Beclin-1 (P < 0.01; Fig. 3.2c), total 
LC3 (P < 0.01; Fig. 3.3c) and increased LC3 II/ LC3 I ratios, comparing 
samples from geriatric vs. young dogs. In contrast, there was lower p62 
expression in muscle tissue samples from geriatric dogs compared with 
those from the young dogs (Fig. 3.4c). 
Cas
e # 
Fiber 
Atroph
y 
necroti
c 
fibers 
Ragge
d and 
Pre-
ragge
d Red 
Fibers 
Rimme
d 
Vacuol
es 
COX 
Negati
ve 
Fibers 
Accumulati
on of 
Lipofuscine
s 
Beclin-
1 
Positivit
y 
LC3 
Positivit
y 
P62 
Positivit
y 
1 
10 to 
50% 
0 0 0 
< 
10% 
10 to 50% 
26–50 
% 
26–50 
% 
0 
2 
> 
50% 
< 
10% 
10 to 
50% 
0 0 0 0 0 0 
3 
< 
10% 
10 to 
50% 
< 
10% 
10 to 
50% 
< 
10% 
> 50% 
> 50 
% 
> 50 
% 
0 
4 
10 to 
50% 
< 
10% 
> 
50% 
0 
10 to 
50% 
10 to 50% 
> 50 
% 
> 50 
% 
0 
5 
10 to 
50% 
0 0 < 10% 0 0 
26–50 
% 
26–50 
% 
0 
6 
10 to 
50% 
< 
10% 
0 0 
< 
10% 
0
 
0 0 0 
7 
> 
50% 
< 
10% 
0 0 0 < 10% 
1–25 
% 
26–50 
% 
1–25 
% 
8 
< 
10% 
0 0 0 0 0 0 0 0 
9 
> 
50% 
< 
10% 
10 to 
50% 
< 10% 
< 
10% 
10 to 50% 
1–25 
% 
1–25 
% 
0 
10 
10 to 
50% 
0 0 0 
> 
50% 
0 
1–25 
% 
1–25 
% 
0 
11 
< 
10% 
< 
10% 
10 to 
50% 
< 10% 0 < 10%
 26–50 
% 
26–50 
% 
1–25 
% 
12 
10 to 
50% 
0 0 0 0 > 50% 
1–25 
% 
1–25 
% 
0 
13 
> 
50% 
< 
10% 
> 
50% 
0 
< 
10% 
10 to 50% 
26–50 
% 
1–25 
% 
0 
14 
< 
10% 
< 
10% 
10 to 
50% 
10 to 
50% 
0 0 
> 50 
% 
> 50 
% 
0 
15 > 0 0 0 10 to 0 1–25 1–25 0 
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50% 50% % % 
16 
< 
10% 
< 
10% 
< 
10% 
> 50% 0 0 
> 50 
% 
> 50 
% 
0 
Cas
e # 
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y 
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c 
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ragge
d Red 
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d 
Vacuol
es 
COX 
Negati
ve 
Fibers 
Accumulati
on of 
Lipofuscine
s 
Beclin-
1 
Positivit
y 
LC3 
Positivit
y 
P62 
Positivit
y 
17 
< 
10% 
0 0 0 
< 
10% 
< 10% 0 0 0 
18 
10 to 
50% 
0 
< 
10% 
< 10% 
10 to 
50% 
0 
> 50 
% 
> 50 
% 
0 
19 
10 to 
50% 
0 0 0 
< 
10% 
< 10%
 
1–25 
% 
1–25 
% 
0 
20 
< 
10% 
< 
10% 
10 to 
50% 
10 to 
50% 
0 < 10%
 26–50 
% 
26–50 
% 
1–25 
% 
21 
10 to 
50% 
0 0 0 0 > 50% 
1–25 
% 
1–25 
% 
0 
22 
> 
50% 
< 
10% 
> 
50% 
0 
< 
10% 
10 to 50% 
26–50 
% 
1–25 
% 
0 
23 
< 
10% 
< 
10% 
10 to 
50% 
< 10% 0 0 
> 50 
% 
> 50 
% 
0 
24 
> 
50% 
0 0 0 
10 to 
50% 
0 
1–25 
% 
1–25 
% 
0 
25 
10 to 
50% 
0 
< 
10% 
< 10% 
10 to 
50% 
0 
> 50 
% 
> 50 
% 
0 
C1 0 0 0 0 0 0 0 0 0 
C2 0 0 0 0 0 0 0 0 0 
C3 0 0 0 0 0 0 0 0 0 
C4 0 0 0 0 0 0 0 0 0 
C5 0 0 0 0 0 0 0 0 0 
Table 3.2 Summary of histopathology and immunohistochemistry results.  
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Fig. 3.2: Immunohistochemical staining for Beclin-1 in biceps femoris muscle. (a) Muscle tissue section showing 
strong expression of Beclin-1 in sarcoplasma and on sarcolemma (arrow). HRP method with Mayer’s 
haematoxylin counterstain. Bar = 50 μm. (b) Representative Western blot evaluating Beclin-1 expression in 
muscle tissue lysates from young and geriatric dogs. β-actin immunoreactivity shown as a loading control. (c) 
Results of densitometric analysis of immunoblots. Data shown represent the mean and SE of the fold increase in 
Beclin-1 expression, normalised against β-actin. Three independent immunoblots were assessed. 
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Fig. 3.3: Immunohistochemical staining for LC3 in biceps femoris muscle. (a) Muscle tissue section showing 
strong expression of LC3 in sarcoplasm (arrow). HRP method with Mayer’s haematoxylin counterstain. Bar = 
50 μm. (b) Representative Western blot evaluating LC3 expression in muscle tissue lysates from young and 
geriatric dogs. β-actin immunoreactivity shown as a loading control. (c) Results of densitometric analysis of 
immunoblots. Data shown represent the mean and SE of the fold increase in LC3 expression, normalised against 
β-actin. Three independent immunoblots were assessed. 
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3. 4 Discussion 
The effect of aging on skeletal muscles in dogs has been investigated 
previously (Braund et al., 1982; Hutchinson et al., 2012), although there 
are substantial gaps in our understanding of this process. In geriatric 
humans and animal models of ageing, several alterations in muscle 
structure and function have been reported in association with an altered 
rate of autophagy. Increased levels of autophagy can exacerbate muscle 
wasting (Mammucari et al., 2007; Zhao et al., 2007; Iovino et al., 2012) 
and accumulation of autophagic vacuoles has been associated with various 
myopathies, such as Danon disease and Pompe disease (Sugie et al., 2005; 
Raben et al., 2007). Furthermore, in murine models of progeria, there is 
enhanced autophagy in various tissues, when compared with wild type 
mice (Mariño and López-Otín, 2008). In the present study, we describe the 
presence of autophagic markers such as Beclin-1 and LC3 in skeletal 
muscles of geriatric dogs, associated with several histochemical features of 
myopathy. The most prominent histopathological findings included fiber 
atrophy, mitochondrial abnormalities in terms of functionality and/ or 
distribution within the cytoplasm, and the presence of esterase positive 
material, consistent with the presence of lipofuscines inside the muscle 
fibers. 
Loss of muscle mass can occur during many catabolic physiological and 
pathophysiological processes, including physical inactivity and starvation 
or anorexia, associated with systemic disease. In our study, we excluded 
dogs demonstrating such conditions in order to evaluate the consequences 
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of the normal ageing process on skeletal muscles. It has been established 
that oxidative stress, occurring with ageing, can contribute to muscle 
atrophy via upregulation of autophagy (Calvani et al., 2013). The markers 
of autophagy that we observed seemed to correlate with the features of 
muscle atrophy. Selective atrophy of the type II fibers can be interpreted as 
an agerelated finding, as described in humans (Nilwik et al., 2013), since 
we excluded dogs that might have other reasons for type II atrophy (e.g. 
due to the presence of an endocrinopathy or following steroid therapy). 
The presence of esterase-positive lipofuscines and mitochondrial 
dysfunction and accumulation inside muscle fibers were other 
prominent histological findings. Lipofuscin formation is a manifestation 
of reactive oxygen species (ROS)-induced damage, and their relationship 
with the lysosomal compartment is also confirmed by the presence of 
esterase-positive vacuoles in several autophagic vacuolar myopathies, such 
as Danon disease and X-linked myopathy with excessive autophagy 
(Nishino, 2007). 
Ageing also leads to increased accumulation of dysfunctional 
mitochondria, associated with mutations in mitochondrial DNA (mtDNA), 
which is particularly vulnerable to ROS-mediated mutagenesis (Terman et 
al., 2010). Since removal of damaged mitochondria occurs via an 
autophagy-mediated process (termed mitophagy), the mitochondrial–
lysosomal theory of ageing has been proposed (Terman et al., 2010). We 
suggest that the progressive accumulation of lipofuscines inside the 
lysosomes can impair mitophagy, resulting in accumulation of 
dysfunctional mitochondria, which contribute to further generation of 
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ROS, increased formation of lipofuscines and, finally, lysosomal 
labilisation with activation of the apoptotic or necrotic pathway. This 
process could potentially explain our research findings in terms of the 
mitochondrial dysfunction and accumulation and presence of lipofuscines 
in skeletal muscle from geriatric dogs. 
Muscle fibers from geriatric dogs often contained rimmed vacuoles and, in 
contrast to samples from young dogs, demonstrated immunoreactivity for 
LC3 and Beclin-1, but not p62. Beclin-1 and LC3 expression indicate 
activation of early and late phases of autophagy, respectively (Tukaj, 
2013). The stress-inducible intracellular protein p62 is involved in many 
signaling responses to growth factors and stress (Tooze and Schiavo, 2008) 
and has the capacity to interact indirectly or directly with both components 
of autophagic machinery and ubiquitin. p62 accumulates due to the 
autophagy blockade, binds to ubiquitinated proteins and prevents their 
delivery and degradation by the proteasome, resulting in a toxic effect 
(Korolchuk et al., 2010). Inefficient fusion between autophagosomes and 
lysosome can lead to accumulation of proteinaceous material, containing 
p62, in the cytoplasm, with decreased levels of ‘free’ p62, associated with 
a high ratio of LC3-II to LC3-I, which is considered to be a further 
indicator of activation of the autophagy pathway (Komatsu et al., 2007). 
It is possible that, with increasing age, formation of dysfunctional 
mitochondria induces muscle cells to enhance mitophagy. However, 
lipofuscine-filled lysosomes might not efficiently degrade this material, 
leading to accumulation of autophagosomes inside the cell, with 
accumulation of damaged mitochondria. Thus, enhanced levels of 
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autophagy in skeletal muscle might represent a prosurvival strategy of 
muscle cells to contrast the progressive accumulation of damaged 
constituents, but finally fail in its original purpose, contributing to muscle 
damage. The cytoprotective function of autophagy is mediated in many 
circumstances by negative modulation of apoptosis (Gordy and He, 2013). 
Thus, evaluation of markers of apoptosis, such as caspase 3, would be an 
interesting avenue of research into canine sarcopenia. Furthermore, 
autophagy dynamics in skeletal muscle appear to be unusual, when 
compared with other tissues. For example, during the fasting state, most 
tissues show a transient activation of autophagy, which only lasts a few 
hours, whereas skeletal muscle shows a more persistent generation of 
autophagosomes that can continue for several days (Mizushima et al., 
2004). Since autophagy is responsible for degradation of several longlived 
proteins as well, this chronic mechanism might contribute to the 
degenerative changes observed in muscle tissue. 
3.5 Conclusions 
The present study provides some insight into the mechanisms 
associated with sarcopenia in dogs as they age. Studying the histological 
features and cellular mechanisms underlying muscle senescence in dogs 
can potentially contribute to our understanding of sarcopenia in humans. 
Comparative ageing research in companion animals that share the same 
environment, diet and exposure to pollutants, etc., makes the canine a more 
realistic model than laboratory rodents. Greater knowledge of the changes 
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that occur in canine skeletal muscle with ageing is also of value to 
veterinary pathologists when undertaking histopathological examination of 
muscle biopsies, allowing them to distinguish changes due to ageing from 
those resulting from disease. 
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4.1 Introduction 
 
The cellular prion protein (PrP
C
) is 250-amino acid sialoglycoprotein 
that is attached to the lipid raft of the plasmamembrane via a C-
terminalglycosylphos- phatidylinositol (GPI) anchor (Stahl et al., 1990). In 
the cell PrPC may be expressed in different glycosylated forms, 
corresponding to the variable occupancy of the residues Asn180 and 
Asn196 (Haraguchi et al.,1989). The C-terminal domain has a rigid and 
distinctive secondary structure, while the N-terminal portion is more 
flexible, unstructured and contains a unique octapeptide repeat (OR) region 
(Zahn et al., 2000). The OR confers PrPC one of its most salient features, 
i.e., the ability to bind divalent cations, prominently copper and to a lesser 
extent zinc, nickel, iron, and manganese (Stockeletal.,1998; Arena et al., 
2012). The OR structure is highly conserved among different species 
(Hornshaw et al, 1995) thus highlighting its important function in defense 
against oxidative stress via reduction of Cu
2+
 to Cu
+
 (Liu et al., 2011). 
PrPC is essential for prion propagation in human and animal prion diseases 
(Transmissible Spongiform Encephalopathies-TSE), characterized by 
accumulation of an aberrant, proteinase resistant, isoform of PrP (called 
PrP
sc
). TSE are a group of neurodegenerative and infectious diseases that 
affects several mammalian species including sheep (scrapie, the prototypi-
cal prion disease), humans (CJD and Kuru), deer (chronic wasting disease; 
CWD) and cattle (BSE). (Prusiner, 1981,1982, 1998; Collinge et al., 2001). 
TSE can have a genetic, infectious, or sporadic origin and are typically 
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marked by neuronal death and astroglial proliferation. In human inherited 
forms of TSE, the formation of PrP
sc
 is secondary to the structural 
instability of mutated prion protein whereas in sporadic and infectious 
forms PrP
sc
 is derived by a post-translational conformational switch of the 
normal prion protein (PrP
c
) to a betasheet enriched disease-associated 
isoform (PrP
sc
). PrP
sc
 is able to accumulate within the CNS owing to newly 
acquired biological and physico-chemical properties such as insolubility in 
nondenaturing detergents, propensity to aggregate and relative resistance to 
protease digestion. Routine diagnostic tests rely on these properties for 
identification of PrP
sc
 in the form of the PK resistant core fragment (PrP
res
) 
(Silva et al. 2015).  
The requisite role of PrP
c
 in TSE (Transmissible Spongiform 
Encephalopathyes) has been unequivocally demonstrated in experiments 
using PrP
c
 knockout mice, since PrP null mice (Prnp0/0) are completely 
resistant to experimental TSE infection (Sailer et al., 1994). 
 
4.1.1 Cellular prion protein in somatic tissues:  
Quantitative analyses of PrP
c
 distribution in the body have been 
reported in several species, revealing that PrP
c
 is expressed in a wide range 
of tissues. However, the amount of PrP
c
 varies significantly between 
different tissues, with highest levels in nervous and lymphoid systems 
(Ford et al., 2002; Horiuki 1995). 
Peralta and colleagues in 2009 analyzed fifteen bovine somatic 
tissues for PrP
c
 expression by quantitative western blot and confirmed 
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highest expression of PrP
c
 in cerebellum, obex and spinal cord. 
Intermediate levels were detected in thymus, intestine, nerve, heart and 
spleen, and lower levels in lung, muscle, kidney, lymph node, skin, 
pancreas and liver (Peralta et al, 2009). Their data showed low (4.2% 
relative to levels in the cerebellum, p < 0.05) levels of PrP
c
 in bovine 
skeletal muscle. This reduced level suggests a low propensity for PrP
c
 to 
PrP
sc
 conversion in skeletal muscle and PrP
sc
 accumulation even in BSE-
infected animals.  
 
Fig. 4.1 expression of PrPc in bovine tissues. From Peralta et al. 2009. 
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4.1.2: Functions of Cellular Prion Protein in nervous system 
The cellular prion protein is known to have a role in neuron 
protection from oxidative stress through antioxidant activity, by sensing 
copper and/or free radical stimuli (Vassallo and Herms, 2003), in 
modulation of calcium entry through NMDA receptor pore by inhibition of 
the channel activity (Cowan et al., 2001; Lo et al., 2007). It has also an 
anti-apoptotic effect on Bax-mediated cell death (Bounhar et al., 2006; Lo 
et al., 2007). PrP
c
 is involved in myelin sheath formation and structural 
preservation through its modulation of β-secretase1 (BACE1) (Parkin et 
al., 2007). 
 
4.1.3: Function and localization of Cellular Prion Protein in skeletal 
muscle  
Most of available information about the function of cellular prion 
protein in skeletal muscle is based on experiments on laboratory animals.  
Prion protein is essential for maintaining normal redox homeostasis, 
muscle size, and contractile function in adult animals (Smith et al., 2011) 
In particular, PrP deficient mice have an age-dependent impairment of 
aerobic performance (Massimino et al., 2016), decreased CuZn-superoxide 
dismutase (SOD1) and catalase (Klamt et al.) and impaired muscle 
regeneration (Stella et al., 2010). Moreover an upregulation of cellular 
prion protein is observed when myotubes differentiate from myoblasts 
(Brown et al., 1998). 
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Although literature data are sparse, it seems that PrP
c
 expression varies 
among species, among muscles, and with age. In general, a detailed 
characterization of PrP
c
 metabolism in skeletal muscles is still lacking; 
According to Smith and colleagues cellular prion protein content varies 
among murine skeletal muscles PrP content differs among mouse muscles 
(gastrocnemius > extensor digitorum longus, > tibialis anterior; soleus > 
diaphragm) as does glycosylation levels (di-, mono-, nonglycosylated; 
gastrocnemius, extensor digitorum longus, tibialis anterior = 60%, 30%, 
10%; soleus, 30%, 40%, 30%; diaphragm, 30%, 30%, 40%) (Smith et al., 
2011). The same authors found that PrP is predominantly di-glycosylated 
in human diaphragm.  
The expression and cellular processing of PrP
c
 change during myogenesis, 
and in muscle fibers with different contractile properties (Massimino et al., 
2006). These authors reported a significantly higher amount of PrP
c
 at 
western blot in tibialis anterior muscle than in soleus, with prevalent di-
glycosylated and unglycosylated form in tibialis anterior and in soleus, 
respectively.  
It’s likely that the PrPc content in different muscle groups reflects the 
relative amount in “fast” (or type 2), and “slow” (or type 1) fibers; indeed 
co-localizing PrP
c
 and fast and low myosin a detectable amount of PrP
c
 
was evident only on fast fibers sarcolemma at immunofluorescence 
(Massimino et al., 2006). 
By immunohistochemistry, PrP
c
 is reported to be normally expressed, at 
low levels, on the sarcolemma and muscle spindles (Zanusso et al., 2001).  
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Moreover, studies using transmission electron microscopy (TEM) and 
immunofluorescence demonstrated PrP
c
 at the level of neuromuscular 
junctions (NMJ) in humans (Gohel et al., 1999). 
 
4.1.4 The cellular prion protein in muscle diseases 
To the author’s knowledge, only few papers focused on the cellular 
prion protein in muscle diseases, and only data restricted to the human 
species are available.  
Increased expression of the cellular prion protein has been reported in 
muscles of human patients with sporadic inclusion-body myositis (s-IBM) 
and hereditary inclusion-body myopathy (h-IBM) (Askanas et al., 1993; 
Sarkozi et al., 1994). These disorders are characterized by an accumulation 
of paired-helical filaments (PHF), amyloid fibrils, hyperphosphorylated tau 
and other pathological proteins within muscle fibers associated with 
chronic inflammation only in the sporadic form (Askanas et al., 1998). 
Muscle inflammation has been reported to facilitate the accumulation of 
PrP
sc
 in muscle in 2 different mouse models of immune-mediated 
inflammatory myopathy (Neumann et al., 2013). 
In 2001 Zanusso et al. described an increased expression of PrP
c
 also in 
human polymyositis, dermatomyositis and neurogenic muscle atrophy. The 
same authors revealed that only PrP
c
, and not PrP
sc
, accumulates in s-IBM 
(Zanusso et al., 2001).  
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4.1.5 The pathological prion protein (PrPsc) in muscle tissue  
It has been shown that prions can also replicate and accumulate in 
skeletal muscles (Bosque et al., 2002; Casalone et al., 2005) raising 
concern about prion transmissibility following ingestion of TSE-tainted 
meat. Sarcoplasmic deposits of PrP
sc
 have been described in the skeletal 
muscle of terminally diseased cows and sheep with infectivity of skeletal 
muscles from affected cattle to transgenic mice (Peden et al. 2006, Suardi 
et al. 2012). PrP
sc
 deposition has been observed inside the cytoplasm of 
isolated fibers with scattered distribution, mainly as small amorphous 
aggregates and, less frequently, in the form of granular deposits (Suardi et 
al., 2012). 
 Pathological prion protein has been demonstrated also in 
semitendinosus/membranosus and gluteal muscles of White-Tailed Deer 
Infected with Chronic Wasting Disease (CWD) in a concentration 2000-
10000 -fold lower than in brain tissue (Daus et al. 2010). 
Low levels of PrP
sc
 were detected in the muscle spindles of the 
masseter, intercostal, triceps brachii, psoas major, quadriceps femoris and 
semitendinosus muscles from 3 field and 6 experimental cases of classical 
bovine spongiform encephalopathy (Okada 2013). 
Joshi-Barr and co-workers in 2014 observed an age-dependent 
degenerative myopathy characterized by ubiquitinated, intracellular prion 
inclusions detectable at immunohistochemistry in transgenic expressing a 
“rigidloop”structural variant of PrP (RL-PrP) (Joshi-Barr et al., 2014). 
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4.1.6: Prion protein and aging. (from Gasperini 2014) 
It is well established that the incidence of prion disease is higher 
with age; this consideration raised the possibility that aging process can 
alter PrP
c
 function influencing its propensity to convert in PrP
sc
. 
Brain aging is related to neuron loss, deterioration of dendrite branches, Ca 
homeostasis changes and increased oxidative stress; all these functions are 
achieved also by prion protein. PrP
c
 is important in memory function and is 
more expressed in the hippocampus. In humans, but not in mice, brain PrP 
content increases with age (Williams et al., 2004), and mice over-
expressing PrP
c
 are protected against some age-related brain changes. 
Biochemical properties that may change with aging thus influencing the 
PrP
c
 propensity to turn in a PrP
sc
 form are:  
1) expression levels: there are conflicting results in different species and 
experiments. Indeed, only in some species PrP
c
 increases with age. 
2) post translational modification (i.e. glycosylation and phosphorylation 
levels). Loss of glycosylation of prion protein has been shown to promote 
acquisition of scrapie-like properties in cultured cells (Lehmann et al, 
2013). Mice studies on aging revealed that there is an increase in 
unglycosylated, truncated form (Xi Hue et al. 2007). Unglycosylated forms 
are more prone to bind cations such as copper, improving its antioxidant 
functions. This also improves prion protein mobility, facilitating PrP
sc
 
propagation in prion disease. 
3) localization in the cell (i.e. inside-outside the lipid raft): a group 
discovered that with aging PrP
c
 moves from the detergent soluble 
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membrane fraction to the lipid raft in aged mice but no amount difference 
(Agostini et al., 2013). 
 
4.2 Aim of the project: 
In the south of Italy the extensive breeding of the autochthonous 
cow breed Podolica is common and many animals are slaughtered in old 
age (>20 years). Those animals commonly show muscle impairment such 
as moderate to severe muscle atrophy, weakness and difficulty walking in 
the absence of any chronic disease. Thus, they are likely to be considered a 
spontaneous model of muscle aging. 
The aim of the present project is to evaluate, by immunohistochemical and 
immunoblot analysis, the presence and the distribution of PrP
c
 in skeletal 
muscle from aged cows compared to muscles from younger animals.  
The possible influence of age related muscle inflammation 
(“inflammaging”- Franceschi et al., 2007) on prion protein expression will 
be considered as well. 
To the best of our knowledge, an attempt to quantify possible age-related 
differences in PrP
c
 content in bovine species has been made only on brain 
samples (Yoshioka et al 2011). In their work, PrPC content does not varies 
between aged (10 years old) and young cows but the amount in the 
detergent-insoluble fraction in the aged cattle was significantly higher than 
that of young cattle. 
Thus, regarding muscle tissue, the two main topics of interest are:  
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a) PrPC physiological localization and characteristics in muscle tissue and 
their putative modification in aging compared to young animals  
2) possible age-related changes in PrPC biochemical properties. The latter 
may be triggered by the cellular aging process and may promote prion 
aggregate formation. 
Muscle cryosections were examined by a standard panel of histological and 
histoenzimatic stains as well as immunohistochemistry for: 
 PrP, to detect its localization in muscle tissue 
 Major Histocompatibility Complex class I, to demonstrate the 
inflammatory activation of muscle fibers even in absence of 
inflammatory infiltrate 
  Desmin, to discriminate degenerated muscle fibers that have a 
reduced signal for desmin  
Immunoblot was performed on muscle and brain homogenates in order to 
analyze the amount of PrPC, its glycosylation profile, proteinase 
resistance, solubility levels after high speed centrifugation and tendency to 
aggregate by sucrose gradient assay. 
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4.3 Materials and Methods  
4.3.1: Animals:  
Skeletal muscle and brain samples of 12 aged (7-22 years old) and 
8 young (1 year old) (table 4.1, figure 4.1) cross-breed Podolica cows were 
collected at the slaughterhouse and immediately (<3 h from collection) 
snap frozen in liquid nitrogen as previously described (Dubowitz and 
Sewry, 2003). 
All the brains were tested BSE negative using mandatory tests for BSE at 
the NeuroCenter (Division of Neurological Sciences, Vetsuisse Faculty, 
University of Bern, Bern, Switzerland). 
 
Case number age (years) Ear brand 
1 12 IT065990027459 
2 1 IT065990382360 
3 1 IT065990423063 
4 11 IT076990040755 
5 1 IT065990426498 
6 1 IT06599039952 
7 16 IT065800846982 
8 19 IT065800830637 
9 15 IT065800858207 
10 12 IT06599007723 
11 8 IT065990171082 
12 22 IT065990029472 
13 7 IT065990171094 
14 1 IT065990029876 
15 1 IT065990040496 
16 12 IT065990027720 
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Case number age (years) Ear brand 
17 7 IT065990217149 
18 13 IT065800905251 
19 1 IT065990425745 
20 1 IT065990425746 
Table 4.1: samples collected, signalment and ear brand of the animals 
 
 
Fig. 4.2: macroscopical pictures of aged cows at the slaughter house. Case number 10 (22 years): the very 
consumed inferior incisors and the yellow subcutaneous fat of the carcass testimonies the old age of the animal.  
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4.3.2: Histology and histochemistry 
For histological and histochemical examination, sections were cut 
in a transverse plane at 10 mm with a cryostat (–20°C) and stained 
according to our routinely performed extensive laboratory stains (Paciello 
and Papparella, 2009).  
Specifically, the following stains were performed: hematoxylin and eosin 
(HE) and Engel trichrome (ET) for a basic morphologic evaluation of 
muscle fibers and intramuscular nerve branches; reduced nicotinamide 
adenine dinucleotide tetrazolium reductase (NADH-TR) to observe 
distribution of mitochondria and the myofibrillar network; succinate 
dehydrogenase (SDH) and cytochrome oxidase (COX) to evaluate activity 
and distribution of mitochondria; nonspecific esterase for the evaluation of 
the neuromuscular junctions and lipofuscins; ATPase at pH 9.4 and 4.3 for 
histochemical fiber type I and II subtyping, respectively;  
Approximately 20 fields at 20x magnification were evaluated for each 
section by 2 independent pathologists (Dr. Teresa Bruna Pagano, Prof. 
Serenella Papparella) with a concordance rate of 95%. 
4.3.3: Immunohistochemistry and immunofluorescence: 
Immunohistochemistry: 8 µm muscle cryosections were air 
drayed for 1h (or with an air dryer, 20 min at cold temperature) and post 
fixed for 3 minutes at 4°C. After washing in tap water for 15 min, the 
endogen peroxidase block: (3% H2O2 in Methanol) was applied for 15 
min. Them the sections were washed in running tap water for 5 min and in 
twice in PBS-T for 5 min. Protein block was performed using Normal Goat 
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Serum (NGS) 5% in PBS for 20 min. Primary antibody (F99: 1:400 
(Neurocenter), L42: 1: 500 (Neurocenter); 1: 300 and 6H4: 1: 500; 1:800 
(Neurocenter) was applied for 1 h at room temperature. After 2 washes in 
PBS-T 2 for 5 min, the secondary antibody (Bottle A -DAKO Kit K5003) 
was applied for 10 min. 
After 2 washes in PBS-T 2 for 5 min, the Secondary antibody (Bottle B - 
DAKO Kit K5003) was used for 10 min. Detection was get using bottle 
ABC (DAKO Kit K5003) for 5- 10 min based on the stain intensity. Then 
the sections were washed in running tap water for 5 min and counterstain 
with hematoxylin. For Desmin, Major Histocompatibility complex Class I, 
CD4, CD8 and MAC 387 antibodies the MACH1 (Biocare Medical, LLC, 
Concord, CA, USA) was used. In brief, the cryosections where incubated 
with primary antibodies (diluted in phosphate-buffered saline) overnight at 
4°C. After 2 washes in phosphate-buffered saline, MACH 1 mouse probe 
(Biocare Medical, LLC, and Concord, CA, USA) was applied for 20 
minutes at room temperature. After, MACH-1 Universal HPR-Polymer 
(Biocare Medical) was added for 30 minutes at room temperature. The 
reaction was detected by DAB chromogen diluted in DAB substrate buffer. 
Finally, sections were counterstained in hematoxylin and mounted in 
aquatex. 
The primary antibodies used are illustrated in table 4.2. 
To confirm the non pathogenic nature of prion protein, selected sections 
were pre-treated with proteinase K.  
Blood vessel endothelial cells within sections were used as internal control 
for MHC I expression. In the corresponding negative control sections, the 
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primary antibody was either omitted or replaced with normal serum from 
the same species of primary antibody (rabbit or mouse). 
 
Immunofluorescence: this technique was used on selected cases in 
order to co-localize PrP and MHC I. 8 µm sections were cut from selected 
muscle specimens on a cryostat and dried at room temperature for 45 
minutes. Sections were fixed in acetone for 10 minutes at 4 °C and after 
were washed three times for 5 minutes with PBS at room temperature. 
Sections were incubated with 10% normal rabbit sera in PBS for 30 
minutes at room temperature and after were washed three times for 5 
minutes with PBS at room temperature. First primary antibody MHC I 
(diluted 1:50 in PBS with 20% normal rabbit serum)) was diluted in PBS 
and 70 µl were added to each section for incubation overnight at 4 °C. On 
control section was added serum diluted in PBS 1:100. After washing three 
times with PBS for 5 minutes at room temperature, in the dark, FITC-
conjugated rabbit anti-mouse IgG (H+L) (1:300; Jackson Laboratories, 
West Grove, PA, USA) was added to each section, except on control 
section where was added only PBS, and incubated for 40 minutes at room 
temperature. The sections were rinsed again in PBS and incubated with the 
second primary antibody against 6H4 (diluted 1:50 in PBS with 20% 
normal rabbit serum) for 24 h at 4 °C. After rinsing in PBS, the sections 
were treated with affinity-purified rabbit anti-mouse IgG-Fab conjugated to 
FITC fluorochrome (1:50; Jackson Laboratories), for 1 h at room 
temperature.  
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For double immunofluorescence staining, fluorochrome conjugated 
Fab fragments were used (Jackson Laboratories) to avoid antibody cross-
reaction using two primary mouse antibodies, according to the method 
previously described (Paciello, 2007). Sections were washed three times 
again with PBS for 5 minutes and mounted under coverslips in 
VECTASHIELD® H-1200 (Vector, Burlingame, CA, USA) to prevent 
fading of fluorescence. 
Specimens were examined and photographed with a laser-scanning 
confocal microscope (LSM-510; Zeiss, Oberkochen, Germany). FITC was 
irradiated at 488 nm and detected via a 505-560 nm band pass filter. 
 
4.3.4 Statistical analysis of histological data:  
To quantify the histological and immunohistochemical findings and 
facilitate statistical analysis, the following three tier score systems were 
applied for each parameter (Table 4.3): 
Finally, an Overall PrP positivity score was obtained by summing PrP+ 
score and PrP+ sarcoplasmic inclusion score.  
All data were imported into a program for statistical analysis 
(GraphPad Prism-GraphPad Software, San Diego, CA). Statistical 
significance was set at P < .05. For each animal, an overall positivity score 
to PrP was obtained by summing the sarcolemmal positivity score and the 
sarcoplasmic positivity score to PrP. All histological scores 
(lymphoplasmacytic inflammation score, fiber degeneration score, angular 
atrophy score, PrP sarcolemmal positivity score, PrP sarcoplasmic 
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positivity score) of young and old animals were compared using the Mann 
Whitney test. Data were checked for normality of distribution with a 
Shapiro-Wilk’s W test. The relationship between IS, histological score, and 
fiber atrophy was evaluated by a Spearman rank correlation test (rs). 
 
score 0: none 1: mild 2: moderate 3: severe 
Lymphoplasmacytic 
inflammation score 
no 
inflammation 
5-25 
inflammatory 
cells x HPF 
(400X) in 10 
fields 
26 to 50 
inflammatory 
cells x HPF 
(400X) 
in 10 fields 
>50 
inflammatory 
cells x HPF 
(400X) 
in 10 fields 
Degeneration score no 
degenerated 
fibers/100 
fibers at 200X 
1-10 
degenerated 
fibers/100 
fibers at 200X 
11-25 
degenerated 
fibers/100 
fibers at 200X 
>25 
degenerated 
fibers/100 
fibers at 200X 
Angular atrophy score no 
angular 
fibers/100 
fibers at 200X 
1-10  
angular 
fibers/100 
fibers at 200X 
1-10  
angular 
fibers/100 
fibers at 200X 
1-10  
angular 
fibers/100 
fibers at 200X 
Sarcolemmal PrP+ 
score 
absent Mild intensity* Moderate 
intensity* 
Strong 
intensity* 
Sarcoplasmic PrP+ 
score 
absent 1-5 positive 
fibers/100 
fibers at 200X 
6-10 positive 
fibers/100 
fibers at 200X 
>10 positive 
fibers/100 
fibers at 200X 
MHC I score absent 1-25 
positive  
26-50 
positive 
fibers/100 
fibers at 200X 
>50  
positive 
fibers/100 
fibers at 200X 
Table 4.2. histological scoring. *=3 the scoring was made by two independent pathologists (OP, TBP) with a 
minimum concordance rate of 95%. In case of discrepancies, the opinion of another pathologist (SP) was 
requested.  
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4.3.5 Sample preparation and western blotting: 
Muscle frozen samples were homogenized at 10% (w/v) in RIPA 
buffer (100 mM NaCl, 10 mM EDTA, 0.5% NP40, 0.5% sodium 
deoxycholate, 10 mM Tris, pH 7.4) in a BIO-RAD 2 ml tube (without 
buffer but with iron beats) and spinned several times in the BIO-RAD 
machine. Brain frozen samples were homogenized at 10% (w/v) in Prionics 
homogenization buffer with a FASTH device (Consul). All samples were 
analyzed with and without PK digestion and/or deglycosylation using 
standard methods. The PK digestion was done with the reagents of the 
Prionics Check Western kit, according to the manufacturer’s instructions 
and at a final PK concentration of 100 lg/ml. For PK titration experiments, 
the PK stock solution was diluted from 1:1 to 1:1000 in 1x homogenization 
buffer. Deglycosylation was performed for 90 min at 37 °C with PNGaseF 
(New England Biolabs) under denaturating conditions according to the 
manufacturer’s instructions. Samples were denatured by boiling in SDS 
sample buffer and resolved on either 4–20% Tris-Glycine gradient gels 
(Life technologies) for epitope mapping, or on 12% Bis-Tris precast gels 
(Life technologies) for all the other experiments. Proteins were then 
transferred to PVDF membranes (Immobilon-P Millipore) for 1hr at 150V. 
PrP probing was done by incubating the membrane with Sha31 antibody 
(0.1 lg/ml, overnight at 4° C) as the primary antibody and a horseradish-
peroxidase rabbit anti-mouse conjugate (Dako) as a secondary antibody, 
unless otherwise mentioned. Antibody binding was visualized with the 
ECL prime reagent kit (GE healthcare) and the LAS3000 
chemiluminescence camera (Fuji). For epitope mapping, we used bovine 
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PrP specific antibodies recognizing epitopes that span from the N-terminal 
to the C-terminal regions, namely SAF32, 9A2, Sha31, and ROS-JB10. 
All the western-blot related experiments were performed according to 
Serra et al, 2016 and performed at the NeuroCenter, Division of 
Neurological sciences, University of Bern, Vetsuisse Faculty, Switzerland. 
   
 
Table 4.3: antibodies and relative techniques used in the study. 
 
Data obtained from quantitative Western blots were analyzed with Image J 
software by Student’s t test. ß-actin and tubulin were used as a loading 
control for brain and muscle, respectively). The autoradiographs shown are 
representative of 4 independent experiments. Bars represent the mean ± SD 
of 4 independent experiments. P values <.05 were considered statistically 
significant. 
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4.3.6 Velocity sedimentation in sucrose step gradient 
Brain and muscle homogenates (10% [w/v]) were prepared in PBS 
with 1% sarcosyl. The supernatant was recovered after pre-centrifugation 
at 1000g for 5 min and was loaded on top of a sucrose gradient, prepared 
by superimposing 350 ll layers of 45%, 40%, 35%, 30%, 25%, 20%, 15%, 
and 10% sucrose solutions from bottom to top. 
The gradients were centrifuged at 200,000g (46,000 rpm) for 65 min at 4° 
C using a P55ST2 rotor and a Hitachi CP100NX centrifuge. After 
centrifugation, the contents of the centrifuge tubes were sequentially 
removed from the bottom to the top to collect. 13 fractions of 
approximately 250 µl each were collected and proteins were precipitated 
and recovered in chloroform and methanol after several spin rounds at 
10,000 rpm for 5 min. The final pellet was resuspended in 50uL PBS + 
0.5% sarkosyl or SDS page sample buffer and stored at -20C until needed. 
The samples were subjected to Western blot analysis to detect PrPC in the 
individual fractions. 
4.3.7 Separation of detergent-soluble and -insoluble PrP by one-
step ultracentrifugation 
Brain and homogenates and detergent-soluble and -insoluble 
fractions were prepared as previously described (Serra, 2016). Briefly, 
10% (w/v) brain homogenates were suspended in 9 volumes of lysis buffer 
(10 mM Tris, 150 mM NaCl, 0.5% Nonidet P40, 0.5% deoxycholate, 5 
mM EDTA, pH 7.4) on ice using a pestle. Five hundred ll of brain 
homogenate was then centrifuged at 1000g for 10 min at 4 °C and the 
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supernatant was collected for ultracentrifugation at 115,000g (35,000 rpm) 
in a P55ST2 rotor and a Hitachi CP100NX centrifuge for 1 h at 4 ° C. 
The supernatant S2 (detergent-soluble fraction) was transferred to a clean 
tube and the pellet P2 (detergent-insoluble fraction) was resuspended in 
500 ll lysis buffer. Half of the volume of S2 and P2 were subjected to PK 
digestion with a final concentration of 50 lg PK/ml (Roche). The other half 
was left undigested. Each sample was boiled at 100 °C for 5 min with an 
equal amount of SDS sample buffer and analyzed by Western blot. 
4.4 Results:  
4.4.1 Histopathology:  
 Main histopathological findings are summarized in table 4.4. 
As expected, muscle biopsies of aged cows showed myopathic features 
(Fig. 4.3 A, B, C) such as degenerated fibers (83%), angular atrophy (75%) 
and lymphocytic inflammation (41%). Those findings were similar to those 
reported in a recent paper from our group (Costagliola et al, 2016). 
Vacuolated muscle fibers and less severe angular atrophy were found in a 
low number of young animals (25 and 12%, respectively). 
Muscle samples from old cows showed also increased variability in 
diameter size of muscle fibers and mild to severe fiber atrophy, multifocal 
subsarcolemmal deposits of SDH (Succinate dehydrogenase) positive 
material, occasional sparse moth-eaten fibers at NADH (Nitroterazolium 
adenine dinucleotide) and reduced central positivity at cytochrome C 
oxidase (COX). ATP-ase stains at pH 4.3 and 9.4 on selected cases 
revealed a predominantly type II fiber in old animals. All those findings 
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were consistent with the typical age related muscular changes previously 
described (Costagliola et al., 2016).  
 
 
 
Fig. 4.3: Cryosections of skeletal muscle from old animals (A: case number 12, B. case number 18; C: case 
number 3). Hematoxylin and Eosin. Original magnification 400X (A) and 200X (B and C). Muscle fiber 
degeneration including sarcoplasmic rimmed vacuole (A) and presence of rigen/degen fibers (B). Endomysial 
lymphoplasmacytic infiltrate (C).  
 
4.4.2: Immunohistochemistry:  
 Immunohistochemistry for PrP
c
 revealed a distinct granular 
positivity in intramuscular nerve branches and muscle spindles in all cases 
(Fig. 4.4). As expected, the signal was completely digested after pre-
treatment with Proteinase K, confirming the presence of only non-disease 
associated prion protein (Fig. 4.5). A faint membrane positivity was 
evident in 60% of cases (Fig. 4.4, B), consisting with a normal constitutive 
membrane expression of PrP. 
The sarcolemma was positive in 37% of young animals and 75% of old 
animals. Sarcoplasmic PrP positive inclusions were detected in 25% of 
young and 75% of old animals. MHC I was overexpressed on the 
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membrane of muscle fibers in 12,5% of young animals and in 66,6% of old 
animals. 
 
 
 
Case 
numb
er 
 
Ag
e 
 
Lymphoplasmo
cytic 
inflammation 
score 
 
Fiber 
degenerat
ion 
score 
 
Angul
ar 
atrop
hy 
score 
 
Prp 
on 
nerv
es 
 
Prp+ on 
sarcolem
ma 
 
PrP+ 
sarcoplas
mic 
inclusions 
 
MH
C I 
scor
e 
 
overall 
PrP 
positiv
ity 
score 
1 12 1 1 0 + 0 1 1 1 
2 1 0 1 0 + 0 1 1 1 
3 1 0 0 1 + 2 0 0 2 
4 11 0 2 1 + 1 0 1 1 
5 1 0 0 0 + 1 0 0 1 
6 1 0 0 0 + 0 0 0 0 
7 16 2 2 2 + 2 2 2 4 
8 19 2 0 2 + 2 1 2 3 
9 15 0 1 1 + 1 1 0 2 
10 12 0 2 2 + 2 1 0 3 
11 8 0 2 1 + 1 2 0 3 
12 22 1 2 2 + 2 1 2 3 
13 7 0 1 1 + 1 1 1 2 
14 1 0 0 0 + 0 0 0 0 
15 1 0 0 0 + 0 0 0 0 
16 12 0 0 0 + 0 0 1 0 
17 7 0 1 0 + 0 1 0 1 
18 13 2 2 1 + 2 0 2 2 
19 1 0 1 0 + 1 1 0 2 
20 1 0 0 0 + 0 0 1 0 
Table 4.4: Histopathology and immunohistochemistry results 
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Fig. 4.4: Normal immunohistochemical findings. PrP (6H4) is expressed in myelin sheath of 
intramuscular nerve branches (A, E), on the sarcolemma (B), at neuromuscular junctions (C) and in 
muscle spindles (D). 
 
Expression and biochemical properties of cellular Prion protein in skeletal muscle of aged cows 
171 
 
 
Fig. 4.5: Normal findings. In all animals, intramuscular nerve branches and muscle spindles stained positively 
to PrP antibody 6H4 (A, B, PK-) but the signal was completely digested after pre-treatment with proteinase K 
(A,B, PK+). Immunohistochemistry (HRP method), hematoxylin counterstain. 
 
A focal subsarcolemmal granular positivity was found in degenerated 
fibers (desmin depleted) of both young (30%) and old (66%) animals with 
an increased immunolabeling of rimmed vacuoles (Fig. 4.7 E). 
Occasionally, mononuclear endomysial infiltrate was PrP positive as well. 
 
Fig. 4.6: Rigen/degen fibers show increased sarcolemmal positivity to PrP (A), decreased desmin signal (B) and 
stain positively to Esterase stain (C). Immunohistochemistry (HRP method) and histochemical stain non specific 
esterase. Original magnification 400X. 
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Fig. 4.7: Pathological findings. PrP is ovrexpressed in angular fibers (A), in regenerating fibers having multiple 
central nuclei (B) that stain positively to desmin (C), in sarcoplamic inclusions (D) and rimmed vacuoles (E). 
Immunohistochemistry (HRP method), hematoxylin counterstain. Original magnification 200X (A) 400X (B).  
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4.4.3 Immunofluorescence:  
On selected cases showing strongest positivity for MHC I at 
immunohistochemistry (n. 5 cases: 1, 7, 8, 12, 14) co-localization between 
PrP
c
 and MHC I on the plasmamembrane was observed (Fig. 4.8).  
 
Fig. 4.8 Immunohistochemistry (left). MHC expression on the sarcolemma of muscle fiber adjacent to 
mononuclear, MHC I positive, inflammatory infiltrate. Immunofluorescence, (right). Cryosection of skeletal 
muscle with age related inflammation. Muscle fibers over expressing MHC I (TRIC- red color) are also more 
immuno-positive to PrP (6H4-green color). Multifocally MHC I and PrP colocalize on the sarcolemma of 
muscle fibers ( merge, orange color).  
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4.4.4 Statistical analysis of histopathological findings 
Lymphoplasmacytic inflammation score was basically higher in old 
compared to young animals, but this difference was not statistically 
significant (P=0.2). The lack of significance can be imputable to the 
presence of mild muscle inflammation of unknown origin in one young 
animal, and interpreted as non-meaningful. 
Fiber degeneration score was significantly (P=0.005) higher in old animals 
compared to young ones (Fig. 4.9 A), as well as angular atrophy (P=0.008) 
(Fig. 4.9 B). PrP sarcolemmal positivity score did not significantly varied 
between young an aged animals (P=0.1) while PrP sarcoplasmic positivity 
score was significantly higher in old animals compared to young animals 
(P=0.03) (Fig. 4.9 B). MHC I score and overall PrP positivity score were 
both significantly higher in old animals compared to young ones (P=0.04 
and P=0.02, respectively. Fig 4.9 C, D). Spearman correlation test revealed 
a positive correlation between fiber degeneration score and PrP 
sarcoplasmic inclusion score (rs=0.5, P=0.07); MHC I score and overall PrP 
score (rs=0.3, P=0.1) were not statistically correlated. Notably, there was a 
positive correlation between age and overall PrP positivity score (rs=0.6, 
P=0.003).  
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Fig. 4.9: Statistical comparison between histological score of young and old cows (only statistically 
significant data are shown).  
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4.4.5 Quantitative western blot 
PrP
c
 showed three poorly distinct migration bands corresponding to 
molecular weights of approximately 35, 30 and 15-16 kDa which are likely 
associated with the di-, mono- and un-glycosylated forms of PrPC, 
respectively. In all experiments, the more distinct band was those at 
35KDa, indicating a possible predominant content of highly glycosylated 
PrP in this tissue. 
 The amount of prion protein detected using Sha31 antibody did not 
vary between old and young animals by statistical analysis; however a 
slightly higher content of PrP
c
 in muscles from young animals was noted 
(Fig. 4.9).  
 
  
 
Fig. 4.9 Quantitative western blot. Representative results of semi quantitative western blotting comparing PrP 
signal in muscle homogenate from old (yellow) and young (green) animals. Tubulin was used as housekeeping 
protein for comparison. No significant differences were noted. Sha31 was used as primary antibody. 
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4.4.6 Glycoprofile and epitope mapping  
The glycoform profile and the molecular mass of PrP
c
 in muscle 
samples appeared slightly different compared to the brain. In particular, 
compared to brain homogenate, the lower, unglycosylated band resulted 
having a higher molecular weight (approximately 2 KDa of difference) 
(Fig.4.10). Enzymatic deglycosylation reduced PrPc species to a 30-kDa 
zone, and to a minor band at ~15 kDa, representing amino-truncated 
fragments (Figure 4.10 arrow). 
Epitope mapping was performed using a panel of different 
antibodies directed against different regions of the prion protein. 
Constantly muscle homogenates showed a different profile compared to 
brain (Fig. 4.11). 
  
 
Fig. 4.10 Western blotting of non deglycosylated and deglycosylated muscle and brain. Representative results 
of brain and skeletal muscle homogenate blot after deglycosylation. The C1 unglycosylated band shows a higher 
molecular weight in muscle tissue after deglycocylation compared to brain. Sha31 was used as primary antibody 
(BDG+= brain deglycosylated, BDG-= brain not deglycosylated, MDG+=muscle deglycosylated, MDG-
=muscle not deglycosylated). 
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Fig. 4.11: Epitope mapping. Left: Representative results of epitope mapping using a panel of different 
antibodies directed against different regions of the prion protein. Constantly muscle homogenates (B) show a 
different profile compared to brain (B). Right: Schematic representation of PrP truncated fragments found in 
health and in disease... Epitopes of antibodies used in this study are indicated on the top (From Serra, 2016). 
 
4.4.7 Proteinase K titration, sucrose gradient, soluble/insoluble 
fraction:  
No significant differences between muscles and brains of young 
and old animals were detected by quantitative immunoblot and Proteinase 
K titration. The signal disappear approximately ad a concentration of 1/100 
of the PK concentration used in Prionics® (Fig. 4.11). 
. 
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Fig. 4.11. PK titration. Representative results of PK titration on muscle homogenate from young (top) and old 
(bottom) animals. Sha31 was used as primary antibody. 
 
Sucrose gradient velocity sedimentation gave variable results, with 
a generally lower amount of PrP in high density sucrose fractions in the 
muscle compared to the brain (Fig. 12, top). After high speed 
centrifugation the majority of muscle PrP
c
 was mainly found in the soluble 
fraction, without significant differences between young and old animals 
(Fig. 4.13). As expected both the soluble and the insoluble fractions were 
totally digested after treatment with Proteinase K (Fig. 4.13, bottom).  
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Fig. 4.12 Sucrose gradient. Representative results of sucrose gradient experiments comparing brain (top) and 
muscle (below) of old and young animals. In the brain PrP signal is still visible at fraction 7, indicating a 
greater tendency of Prion Protein to form aggregates in old animals compared to young. Such difference is not 
observed in the comparison between sucrose gradient of muscle tissue from old and young animals. Sha31 was 
used as primary antibody. 
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Fig. 4.13 Soluble-insoluble fractions Representative results of soluble/insoluble fraction experiments on muscle 
homogenates from young and old animals. After high speed centrifugation the majority of muscle PrPC was 
found in the soluble fraction, without significant differences between young and old animals. The signal is 
completely digested after treatment with PK (PK+). 
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4.5 Discussion: 
The prion protein has become sadly popular after the outbreak of 
Prionic diseases (TSE) in human population. During recent years, however, 
increased scientific evidences suggested that its cellular variant (PrP
c
) has 
several important physiological functions, being involved in protection 
against oxidative stress, in myelin sheath integrity maintenance, in calcium 
homeostasis and so on (Cowan et al., 2001; Lo et al., 2007, Vassallo and 
Herms, 2003 Gasperini et al., 2014). In the brain, PrP
c
 has also been shown 
to inhibit the production of amyloid-β, and an age-related impairment of 
brain PrP
c
 has been proposed as a factor involved in increased incidence of 
Alzheimer disease in older people (Whitehouse, 2011).  
Nevertheless, information on cellular prion protein features, functions and 
metabolism in non neural tissues is still largely unavailable and most of 
research has been focused on PrP
res
 and nervous tissue.  
Skeletal muscle is one of the most unexplored tissue in this field despite its 
potential key role in the transmission of prionic disease as a route for 
human disease. In experimental prion disease skeletal muscle has been 
proved to propagate prions and accumulate substantial titers of these 
pathogens (Bosque et al., 2001, Okada et al, 2013); infectivity in skeletal 
muscle of cattle with atypical bovine spongiform encephalopathy has been 
described as well (Suardi, 2012). 
Here, we present preliminary results about PrP
c
 features in skeletal muscle. 
To the author’s knowledge, this is the first report about PrPc expression 
and biochemical properties in bovine muscle tissue. We tried to better 
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characterize the localization and the biochemical properties using 
innovative techniques that are commonly used to study PrP
res
 on the 
nervous tissue of diseased animals.  
At first, much work was needed to adapt these techniques (i.e. sucrose 
gradient, soluble insoluble fractions, glycosylation profile etc.) on muscle 
tissue, in which the PrP
c
 is expressed in an extremely low amount 
compared to the brain (5%).  
The main results of the present study suggest that: 
1) PrPc is normally detectable by immunohistochemistry in 
intramuscular nerve branches, muscle spindles and neuromuscular 
junctions in bovine frozen muscle tissue. 
2) PrPc is overexpressed in degenerated, vacuolated and angular 
atrophic muscle fibers as well as in muscle inflammation. 
3) The glycoform profile of PrPc differs between brain and muscle 
tissue.  
4) The gylcoform profile did not varied between young and old 
animals. 
5) Detergent solubility, PK resistance and PrPc tendency to 
aggregation in skeletal muscle do not vary with age. 
The first finding is in accordance with human literature (Zanusso et al. 
2014) but has been never reported before in bovine skeletal muscle. 
Notably, previous papers reported a negative result at 
immunohistochemical detection of PrP
c
 in formalin fixed skeletal muscle 
tissue (Peralta, 2009), and only immunodetection of PrP in animal and 
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human individuals terminally affected by prion diseases has been described 
so far (Okada et al. 2013, Peden, 2006, Daus, 2011). In contrast, we found 
a distinct sarcolemmal and neural positivity to 6H4 antibody; it is likely 
that this result is imputable to the better antigenity quality that is typical of 
frozen tissues compared to formalin-fixed tissues. Moreover, we found that 
the antibody 6H4 works better on cryosections compared to F99, the most 
commonly used antibody to detect prion protein for diagnostic purpose on 
formalin fixed sections.  
The second finding confirms the possible involvement of PrP
c
 in 
inflammatory and neurogenic muscle disorders also in bovine species. We 
found that muscle fibers in inflamed muscles displayed a higher positivity 
to PrP
c
. This result is consistent with previously literature regarding the 
expression of prion protein in human inflammatory myopathies (Zanusso 
et al, 2014) and mouse models of inflammatory myopathies (Neuman, 
2013). In particular, in the last paper, the authors observed, in early disease 
stages, that PrP
sc
 accumulation is driven by cells of hematopoietic origin, 
whereas at late disease stages, non-hematopoietic cells such as myocytes 
represent the main sites for PrP
sc
 accumulation. Since this accumulation is 
transient, the authors suggested that skeletal muscle has an intrinsically 
high ability to clear PrP
sc
 once myositis has ceased, possibly by means of 
autophagy (Neuman 2013). Joshi-Barr and colleagues in 2014 inhibited 
autophagy in vitro cultures of C2C12 myoblasts, and observed enhanced 
intracellular prion accumulations; thus, they proposed a role for autophagy 
in prion aggregate clearance. As further support of this hypothesis, 
Furukawa and colleagues in 2004 reproduced an experimental myopathy 
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implying a drug-induced blockage of autophagy in hamsters and found an 
anomalous accumulation of PrP in skeletal muscle (Furukawa, 2004). For 
future perspectives, it will be interesting to explore the association between 
prion expression and autophagy markers, possibly in old animals compared 
to young ones.  
The reasons for the over-expression of prion protein in degenerated muscle 
fibers are unknown but, given the antioxidant properties of this protein, it 
may represent a cellular response to altered homeostasis typical of 
degenerative conditions.  
The glycoform profile of prion protein has been largely studied in prion 
diseases. Atypical BSE (Casalone, 2004, Biacabe, 2004), indeed, differs 
from the classical form (C-BSE) based on a different glycoprofile of the 
PK resistant protein at western blot analysis. H-type is characterized by a 
higher molecular mass of the unglycosylated protein band, and L-type, or a 
bovine amyloidotic spongiform encephalopathy (BASE), is characterized 
by an unglycosylated protein band with a lower molecular mass. Sporadic 
reports of prion disease (H-type BSE) in cattle occurring after the ban of 
meat based food in 2001, has raised the hypothesis that the etiology of H-
type BSE may be unrelated to the ingestion of prion-contaminated meat-
and bone meal and the need for more knowledge about how the cellular 
prion protein may transform without being in contact with an exogenous 
source of PrP
res
 (Guldimann, 2012). Since most atypical BSE cases have 
occurred in cattle over 8 years of age, Yoshioka and coworkers in 2010 
studied the biological properties of normal prion protein in the brain of 
young and aged cattle in order to clarify the existence of any relationship 
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between cattle age and occurrence of atypical BSE. They found that the 
amount of PrPC in the brain homogenates was not significantly different 
between young and aged cattle, but the amount in the detergent-insoluble 
fraction in the aged cattle was significantly higher than that of young cattle. 
In our work nor the total amount, nor the amount of detergent insoluble 
fraction nor the susceptibility to PK digestion varied between young and 
old animals, suggesting a different metabolism of prion protein in those 
two tissues. The different glycoprofile that we found between brain and 
tissue may be responsible for a different susceptibility of muscle tissue to 
propagate prions of atypical BSE, but this hypotheses needs to be further 
investigated. A similar finding was previously reported by Zanusso and 
colleagues in 2014.  
In conclusion, in this final part of the thesis, we present preliminary results 
about cellular prion protein in muscle tissue. Although we didn’t confirm 
the starting hypothesis of a possible age-related modification in the prion 
protein properties and expression, we described for the first time the 
overexpression of PrPC in muscle degeneration, inflammation and 
neurogenic atrophy in bovine species, opening new perspectives for the 
future study about the molecular bases of these findings.  
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Conclusions: 
 
 The study of muscle pathology in veterinary medicine is a 
relatively young field of research which offers countless scientific insights 
about the pathogenesis of human and animal diseases, as well as about the 
validation of animal models in comparative medicine. 
 In these three years of scientific activities specific aspects about the 
etiopathogenesis of inflammatory myopathies and muscle aging have been 
investigated in four species of veterinary interest including horses, sheep, 
dogs and cows.  
The main innovative aspects of this thesis are: 
1) The first description in the literature of a likely immune-mediated 
myositis occurring in horses with chronic piroplasmosis 
2) The demonstration of high prevalence of lymphoplasmacellular 
myositis in ovine muscular sarcocystosis characterized by the 
overexpression of MHC I and II on muscle fibers as well as on the 
cyst wall. 
3) The report of enhanced autophagy in age-related muscle atrophy in 
dogs. 
4) The first detailed description of cellular prion protein (PrPC) 
localization and biochemical properties in bovine muscle tissue and 
its possible involvement in neurogenic atrophy, muscle 
degeneration and chronic inflammation.  
Our preliminary observations may open several new perspectives in the 
study of just listed subjects.  
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In particular, it would be of special interest to better characterize the 
possible autoantigens triggering muscle inflammation in equine 
piroplasmosis, as already started by other researchers from our group in 
Leishmania-related myositis. The first step in this direction is to confirm 
the sarcolemmal location of these proteins using samples of sarcolemmal-
pure homogenates by western blot by means of sera from affected animals 
as primary antibody. Then, further co-localization experiments between 
sera auto-antibodies and sarcolemmal protein would give useful 
information in validating selected sarcolemmal proteins as autoantigens.  
The role of MHC I overexpression on the wall of sarcocysts has been of 
particular interest in this thesis. In a future perspective it would be 
interesting to study this phenomenon in experimental infections or in cell 
cultures of muscle fibers paying particular attention to the timing of onset 
of this feature. Indeed, it is still unknown whether the presence of this 
marker on the cyst wall may depend on a still incomplete extrusion of host 
cell protein from the parasitophorous vacuole or it is a consequence of a 
late activation of muscle fiber finalized to stimulate an inflammatory 
response against the parasite.  
Information about the molecular mechanism underlying muscle aging in 
animals is still largely laking in veterinary medicine. Here we focused on 
one of the mechanism involved in muscle fiber proteostasis. In the future, 
it will be important to evaluate also other pathways possibly involved in 
muscle aging, such as the ubiquitin-proteasome system and oxidative 
stress.  
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The results of the project about prion protein in muscle tissue suggested a 
main link between the over-expression of this protein in a variety of 
pathological conditions of muscle fibers independently from the age. This 
concept may open new perspectives in the study of prion protein in muscle 
diseases, ranging from the inflammatory immune-mediated and infective 
myopathies to degenerative diseases in different species of veterinary 
interest. 
In conclusion, we 1) added new scientific data to the veterinary literature in 
the field of muscle pathology that may serve as starting point for new 
research projects and 2) enhanced the pivotal role of histomorphological 
studies in the discovery of new pathogenetic aspects of muscle diseases in 
animals and possibly in humans.  
 
